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ABBREVIATIONS 
2-NBDG - 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose 
AGM - aorta-gonads-mesopnephros 
AKT- Protein Kinase B 
ALOX15- Arachidonate 15-lipoxygenase 
ANOVA - Analysis of variance 
AP1 - Activated protein-1 
APS - Ammonium persulfate 
ARRDC4 - Arrestin Domain Containing 
BHQ1 - Black Hole Quencher-1 
BMDM - Bone-marrow-derived macrophage 
BMI – Body mass index 
BSA - Bovine serum albumine 
C2H2 – Zinc finger-SET histone methyltransferase 
CBP -  CREB-binding protein 
CCL - C-C Motif Chemokine Ligand 
CD – Cluster of differentiation 
CGI - CG-islands CGI 
ChIP – Chromatin immunoprecipitation 
CNS - Central nervous system  
CO2 - Carbon dioxide 
COPD - Chronic obstructive pulmonary disease 
COX – Cyclooxygenase 
CSF1/M-CSF - Colony stimulating factor  
CVD – Cardiovascular disease 
DAMP - Damage-associated molecular patterns 
DAPI - 4′,6-diamidino-2-phenylindole  
DMSO - Dimethylsulfoxide 
DNA –  Deoxyribonucleic acid 
DNMT – DNA methylase 
dNTP - Deoxynucleotide 
EDTA - Ethylenediaminetetraacetic acid 
ELISA - Enzyme-Linked Immuno Sorbent Assay 
ENCODE - Encyclopedia of DNA Coding Elements  
ER – Endoplasmatic reticulum 
ERK - Extracellular-signal-regulated kinase 
FACS - Fluorescence-activated cell sorting 
FAM - Fluorescein amidite 
FCS - Fetal bovine serum 
FFA – Free fatty acid 
FG – Fasting glucose 
FPN1 - Solute carrier family 40 protein 
Fru-2,6-P2 - Fructose-2,6-biphosphate 
GLO1 - Glyoxalase I 
GLUT - Glucose transporter 
GR - galactose receptor 
GSK – Glycogen synthase kinase 
H2O – Hydrogen 
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H3 – Histone 3 
HAT – Histone acetyltransferase 
HbA1c - Hemoglobine A 1c 
HDAC – Histone deacetylase  
HDL - High-density-lipoproteïne 
HDM – Histone demethylases  
hESCs - Human embryonic stem cells 
HG – Hyperglycemia 
HIF - Hypoxia-inducible factor  
HLA - Human leukocyte antigens 
HMGB1 - High mobility group box 1 
HMT - Histone methyltransferases 
HO-1 - Heme oxygenase-1 
HSCs - Hematopoietic cells 
IDH - Isocitrate dehydrogenase 
IFN – Interferon 
IFNAR – Interferon-α/β receptor 
IKK - IκB kinase 
IL – Interleukin 
iPSCs - Induced pluripotent stem cells 
IR – Insulin resistance 
IRF - Interferon regulatory factors 
JMJD - Jumonji domain-containing 
KEGG - Kyoto Encyclopedia of Genes and Genomes 
KLF - Krüppel-like factor 4 
LDL - Low-density lipoprotein 
LDTFs - lineage-determining factors  
LOX-1 – Lectin-type oxidized LDL receptor 1 
LPS – Lipopolysaccharide 
MAPK - Mitogen-activated protein kinase 
MCP-1 - Monocyte chemoattractant protein 1 
MLL –  mixed-lineage leukemia 
MMP - Matrix metalloproteinases 
mPGES - PGE synthase  
NADPH  - Nicotinamide adenine dinucleotide phosphate 
NF-kB - Nuclear factor kappa-light-chain-enhancer of activated B cells 
NLRP3 - pYRIN domain-containing 3  
NO  - Nitric oxide  
NOS – Nitric oxide synthase 
OXPHOS - oxidative phosphorylation 
PA - Palmitic Acid  
PBMCs - Peripheral blood mononuclear cell 
PBS - Phosphate-buffered saline 
PCAF – P300/CBP-associated factor 
PCR - Polymerase chain reaction 
PFA - Paraformaldehyde 
PFK - 6-Phosphofructo-2-kinase  
PI3K – Phosphatidylinositol 3-kinase 
PKC – Protein kinase C 
PKM2 - Pyruvate kinase M2  
PMA - Phorbol 12-myristate 13-acetate 
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PPAR - Proliferator-activated receptor 
PRC - Polycomb regulatory complexes  
PRDM9 - PRDI-BF1 and RIZ homology domain containing  
RAGE - Receptor for Advanced Glycation Endproducts 
RANTES – Regulated upon Activation, Normal T cell Expressed, and Secreted (CCL5) 
RNA - Ribonucleic acid 
RNApII – RNA polymerase 2 
ROS – Reactive oxygen species 
SAM - S-Adenosyl Methionine 
SDS - Sodium dodecyl sulfate 
SDTFs - Signal-dependent transcription factors  
SET – SET domain containing  
SFM – Serum free medium 
SMYD – SET and MYND domain-containing protein 
SOCS - Suppressor of cytokine signalling 
SOD2 - Superoxide dismutase 2 
STAT - Signal transducer and activator of transcription 
SWI/SNF - SWItch/Sucrose Non-Fermentable 
T1D – Type 1 Diabetes 
T2D – Type 2 Diabetes 
TAE - Tris-acetate-EDTA 
TCA cycle – Tricarboxylic acid cycle 
TET – Ten-eleven Translocation Enzymes 
TF - Transcription factor 
TGF - Transforming growth factor 
THP-1 – Human acute monocytic leukemia cell line 
TLR - Toll-like receptor  
TNF – Tumor necrosis factor 
TSS - Transcription start site 
TXNIP - Thioredoxin interacting protein 
UCP1 – Uncoupling protein 1 
UDP-GlcNAc - UDP-N-acetyl-alpha-D-glucosamine  
VEGF - Vascular endothelial growth factor 
WDR5 - WD repeat-containing protein 5 
YS – Yolk sac 
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1 INTRODUCTION 
1.1 Diabetic pathology, vascular complications and macrophages  
Diabetes confers to about two-fold higher risk for a wide range of vascular diseases, 
independently from age, sex, smoking, systolic blood pressure, and BMI (Mathers and Loncar 
2006, Collaboration 2010, The Emerging Risk Factors 2010). Hyperglycaemia concerns the 
increases of glucose in the blood plasma. Chronic hyperglycemia can vary depending on an 
individual renal threshold of glucose and glucose tolerance, the renal threshold, being the 
point at which glucose is excreted in the urine (DeFronzo, Hompesch et al. 2013). The 
diagnosis of diabetes is made after measuring blood glucose in either fasting state of 2 hours 
post glucose challenge. The majority of patients with Type 1 Diabetes (T1D) develop 
complications later in life (Katsarou, Gudbjörnsdottir et al. 2017) and higher HbA1c levels, 
glycated haemoglobin which reflects blood glucose over time, is associated with all-cause 
mortality (Orchard, Nathan et al. 2015). Diabetic retinopathy is an important cause of 
blindness (Bourne, Stevens et al. 2013) while diabetic nephropathy is one of the most serious 
complications of diabetes as well as leading cause of end-stage renal disease (Gillespie, 
Morgenstern et al. 2015). In T1D a genetically determined susceptibility may explain why not 
all individuals with very high blood glucose levels or vice versa some individuals with only 
slightly elevated levels develop complications (Reichard 1995). In case of Type 2 Diabetes 
(T2D) the patient is often diagnosed only at advanced disease stage and long-term 
complications may be already present at the time of diagnosis. The lack of insulin (T1D) or 
lack of insulin responsiveness (T2D) causes metabolic changes such as hyperglycemia which 
contributes to the pathology of diabetes. Hyperglycemia undesirably and unnecessarily 
activates immune responses and thus supports inflammation (Donath and Shoelson 2011, 
Chang and Yang 2016). Macrophages are essential regulators of inflammation and play a 
critical role in diabetic microvascular complications. In diabetic retinopathy activated resident 
macrophages produce inflammatory and neurotoxic mediators leading to vascular degradation 
break down (Altmann and Schmidt 2018). Macrophage recruitment and activation contribute 
to diabetic nephropathy (Tesch 2010) and neuropathy (Sandireddy, Yerra et al. 2014). Lastly, 
loss of plasticity of macrophages has been hypothesized to mediate delayed wound healing 
seen in diabetic patients (Boniakowski, Kimball et al. 2017). Therefore, diabetic 
complications result from an abnormal metabolic environment laundered by chronic 
hyperglycemia. 
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1.2 Diversity and plasticity of macrophages 
Macrophages are the first line of defence against pathogens and essential for the control of 
tissue homeostasis. Their broad range of functions and prevalence probably contribute to the 
fact that they are involved in wide range of pathologies and makes it essential to understand 
how macrophages sense and respond to environmental cues (Asmis 2016).  
The general dogma was that proliferating promonocytes, the bone marrow progenitor cells, 
give rise to circulating monocytes that extravasate into the tissue and maturate there into 
macrophages. Now it seems that, tissue resident macrophages are derived from the circulating 
monocytes as well as monocyte-independent systems (Ginhoux and Jung 2014). 
Haematopoiesis is characterised by two phases, primitive and definitive. Where the primitive 
phase takes place in the yolk sac (YS) through which erythrocytes and macrophages are being 
generated, the definite includes the generation of hematopoietic cells (HSCs) which give rise 
to the major blood cell lineages (Orkin and Zon 2008). The definite phase of haematopoiesis 
takes place in the aorta-gonads-mesopnephros (AGM) in the embryo. From there the cells 
relocate to various tissues e.g. the liver, spleen and bone-marrow where they reside 
throughout adult life. The anatomical sites and phases of haematopoiesis are depicted on 
Fig.1.  
 
Figure 1. HSC generation, maintenance, and expansion during embryonic development in 
humans. The first HSCs are made outside of the embryo (YS, allantois, placenta) and finally in the 
AGM region and placenta. After that they migrate and expand into the different tissues. Cold Spring 
Harb Perspect Biol 2012;4:a008250, with copyright to Cold Spring Harbor Laboratory Press Rieger 
and Schroeder 2012. 
Lineage definition and tracing in mice revealed certain pathways regulating distinct functions 
of embryonic and adult macrophages. For example, microglia are mostly derived from YS, 
e.g. primitive instead of definite haematopoiesis, and for their self-renewal do not depend on 
monocytes (Ajami, Bennett et al. 2007), whereas macrophages in the intestine, marginal zone 
of the spleen and uterus rely on constant inflow of monocytes. At the same time, macrophages 
at other locations including lung, liver and epidermis display a mixture of HSCs from both 
INTRODUCTION   
11 
 
origins (Yona, Kim et al. 2013). Tissue-resident macrophages although derived from common 
lineage still greatly vary in function and phenotype (Haldar and Murphy 2014). For example, 
the red pulp macrophages in the spleen are responsible for phagocytosis of old and damaged 
erythrocytes, iron recycling as well as clearance of B cells and immune surveillance. The 
alveolar macrophages in the lung control surfactant homeostasis and modulate dendritic cells 
in preventing allergic reactions and lastly, microglia in the central nervous system (CNS) 
promotes normal neuronal development and function (Haldar and Murphy 2014).  
The hematopoietic system is identified as highly responsive to the physiological demands of 
the whole body e.g. development, homeostasis and repair (Okabe and Medzhitov 2015). At 
the same time, tissue-resident macrophages employ their local homeostatic mechanisms in 
order to maintain the number of cells i.e. by proliferating or recruitment of precursor cells 
(Haldar and Murphy 2014). The terminal differentiation and phenotype of the various types of 
resident macrophages likely depends on tissue-specific signals e.g. ‘identity’ signals as well 
as signals that mediate local functional demands (Okabe and Medzhitov 2015).  
The phenotypes and transcriptional programs of macrophages are defined by a combination of 
differentiation and polarisation. Differentiation of macrophages is the stable irreversible 
conversion of progenitor cells by promotion of distinct differentiation paths, whereas 
polarisation is the stable and reversible programming on a specific demand in space and time 
(Okabe and Medzhitov 2015, Murray 2017). Activation of macrophages is broadly grouped in 
two activation phenotypes which occur during exposure with polarized CD4+ Th1/Th2 cells. 
M1 macrophages develop during inflammatory settings and activation usually occurs through 
Toll-like receptor (TLR) and interferon signalling, for example in response to bacteria and 
other pathogens. M2 activation in contrast, is associated with immune response during asthma 
and allergies (Biswas, Chittezhath et al. 2012, Murray 2017). For simplicity, cost 
effectiveness and time sake, in cell culture survival cytokines and polarizing agents are being 
used to study M1 and M2 macrophages. For M1 polarisation IFNγ and/or TLR agonist such 
as LPS, versus stimulation with IL-4, IL-10, IL-13, immune complexes, or glucocorticoids for 
the generation of M2 polarised macrophages (Fraternale, Brundu et al. 2015). The stimuli 
induce unique inflammatory profiles i.e. IFNγ polarized macrophages showed an autocrine 
feedback induction of cytokines and LPS induced macrophages higher secretion of IL-8, 
TNF-α, RANTES and IL-1β (Tarique, Logan et al. 2015). M1- and M2- polarisation states are 
presented schematically (Fig. 2 derived from (Biswas, Chittezhath et al. 2012). 
The change in macrophage phenotype as a consequence of pathogenic or environmental 
signals show the great functional versatility of the cells and their ability to tailor the 
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appropriate response (Biswas, Chittezhath et al. 2012). Functional diversity of macrophage 
include triggering of inflammation, immune-regulation by secretion of anti-inflammatory 
factors such as IL-10 and TGF-β, but also phagocytosis of pathogens, clearance of debris and 
dead cells, and tissue remodelling through secretion of VEGF, CSF1, IL-8, MMP9 and 
polyamines that promote angiogenesis and fibrosis (Biswas, Chittezhath et al. 2012).  
Figure 2. Schematic representation of the macrophage M1- and M2- polarisation states. 
Reprinted from Immunologic Research 53(1). Macrophage polarization and plasticity in health and 
disease. Biswas, S. K., M. Chittezhath, I. N. Shalova and J.-Y. Lim. 2012. with permission Springer 
Nature. SR scavenging receptor, MR mannose receptor, GR galactose receptor. 
 
In vitro studies confirm the reversibility of polarisation states i.e. in cytokine deficient 
medium; both M1 and M2 polarized cells lost their phenotype after 6 days. Authors were also 
able to demonstrate repolarisation; after LPS + IFNγ treatment previous M2 cells exhibited 
CD64 and CD80, M1 like surface markers whereas previous M1 cells upon exposure with IL-
13 showed upregulation of CD11 and CD209 but not CD1a, -b and CD200R (Tarique, Logan 
et al. 2015). Another study also reported that M2 polarizing stimuli abrogate all IFN-
associated pathways, though it seems that macrophages respond differently to different types 
of M2-polarizing stimuli. For example, IL-4 and IL-10 lead to opposite responses compared 
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to LPS in repolarized human macrophages (Gharib, McMahan et al. 2019). Notably, other 
scientist report failure to repolarise M1 into M2 which depended on dampened mitochondrial 
oxidative respiration by nitric oxide (NO). Repolarisation then was successful after inhibition 
of NO production (Van den Bossche, Baardman et al. 2016). 
 
 
Figure 3. Signalling pathways involved in macrophage polarization. Reprinted from Cell 
Metabolism, 15(6), Subhra K. Biswas,Alberto Mantovani. Orchestration of Metabolism by 
Macrophages, 432-437, Apr 4, 2012 with permission from Elsevier.  
 
In vivo, during the course of inflammation and its resolution, cells undergo transition from an 
M1 to M2 phenotype like macrophage. The huge role of macrophage plasticity in different 
disease settings, such as tissue regeneration, tumorigenesis, fibrosis and fat metabolism has 
increased the importance of understanding its regulation and opportunities to modulate 
(Biswas, Chittezhath et al. 2012, Helm, Held-Feindt et al. 2014, Pan, Liu et al. 2015, Alvarez, 
Liu et al. 2016, Chistiakov, Myasoedova et al. 2018).  
The regulation of macrophage plasticity occurs on the level of signalling, through 
transcription factors, at epigenetic level and by miRNA’s (paragraph 1.5, this thesis) and 
aforementioned microenvironmental signals. The effect of hypoxia is the mediated by 
transcription factor hypoxia-inducible factor (HIF) 1α and 2 (Fang, Hughes et al. 2009). 
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Signalling pathways involved in macrophage polarization are depicted in Fig. 3 derived from 
(Biswas and Mantovani 2012). INFγ and LPS signal through IFNAR1 and TLR4 thereby 
activating the transcription factors NF-kB (via IKKb), AP1, IRF3, and STAT1 which 
eventually leads to the transcription of M1 genes. In contrast, IL-4 and IL-13 act via IL-4 
receptor to activate STAT6 and regulate the expression of M2 genes. The nuclear receptor 
peroxisome proliferator-activated receptor-γ (PPARγ) and Krüppel-like factor 4 (KLF4) and 
IRF4 transcription factors are also linked to M2 macrophage polarization as well as the 
histone demethylase Jumonji domain-containing 3 (JMJD3) (Biswas and Mantovani 2012).  
The polarisation states are linked to their functional metabolic outcomes (Fig. 3). 
Macrophages are important in homeostasis of metabolism of tissues as well as whole body 
metabolism whereas on the other side, the intrinsic metabolism of the cell shapes its activation 
state, (Biswas and Mantovani 2012). There is growing interest in understanding macrophage 
polarization under physiological and pathophysiological conditions and the relationship 
between metabolism and macrophage polarization. Metabolic regulators then could be used as 
modulators or switches between polarisation states (Murray 2017). Therefore, the regulation 
of macrophage polarisation at cell metabolism level will be discussed in the following 
paragraph. 
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1.3 Metabolism in differentially activated macrophages 
Polarisation of macrophages greatly depends on biochemical pathways. For example,  
glutamine, fatty acid uptake, CD36 metabolism and mitochondrial oxidative phosphorylation 
are essential for the development of M2 macrophages (Huang, Everts et al. 2014) whereas M1 
macrophages rely on glycolysis for their energy supply (O'Neill and Pearce 2016). Therefore, 
the major metabolic pathways will be described here. 
Glucose metabolism: typically differentiated cells have low rates of glycolysis. During 
glycolysis glucose is converted into pyruvate. Pyruvate subsequently is oxidized in the TCA 
cycle in order to generate ATP. M1 and M2 polarized macrophages are fuelled from different 
energy sources. IFNγ/LPS trigger in macrophages an increased rate of glycolysis followed by 
lactic acid fermentation. This is due to concomitant increased expression of 6-Phosphofructo-
2-kinase (PFK2) isoforms from the liver-type PFK2 (L-PFK2) to the more active and 
ubiquitous PFK2 isoform (uPFK2), which ultimately results in higher levels of Fructose-2,6-
biphosphate (Saha, Shalova et al. 2017). The conversion of glucose into lactate however 
yields only two ATP per glucose molecule compared to 32 when following complete 
oxidation into CO2 and H2O. Lactate is normally produced under low oxygen conditions, in 
the presence of oxygen this process will be called aerobic glycolysis and the shift from 
mitochondrial oxidation towards aerobic glycolysis the Warburg effect which is mediated via 
the NF‑ κB/HIF‑ 1α pathway (Odegaard and Chawla 2011, Saha, Shalova et al. 2017). 
Though, in M1 macrophages the TCA cycle is fragmented at two steps; after isocitrate 
dehydrogenase (IDH) and after succinate the cycle is broken leading to accumulation of 
citrate and succinate (O’Neill 2015, Saha, Shalova et al. 2017). In contrast, IL-4 activated M2 
macrophages display an intact TCA cycle and rely on fatty acid oxidation as metabolic 
pathway in order to fulfil their energy demand for their role in tissue remodelling, wound 
healing and repair (Odegaard and Chawla 2011). Also, M2 macrophages are characterized by, 
high amounts of amino-sugar and nucleotide sugar mark high level of UDP-N-acetyl-alpha-D-
glucosamine (UDP-GlcNAc) and are needed for glycosylation of the lectin/mannose receptor 
in M2 macrophages. Glutamine also appeared to be essential for M2 macrophage 
differentiation (Sica and Mantovani 2012, Jha, Huang et al. 2015). 
A changed lipid metabolism contributes to the macrophage activation; fatty acid uptake is 
suppressed in M1 compared to M2 macrophages the latter one showing increased fatty acid 
uptake and oxidation. The changes in lipid metabolism are associated with regulatory changes 
in transcriptional profile and lipid mediators and kinases (Martinez, Gordon et al. 2006, 
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Biswas and Mantovani 2012) and provides energy needed for phagocytosis but also 
membrane elasticity required. Genes related to arachidonate metabolism which are up 
regulated in M1 macrophages are COX2 and microsomal PGE synthase (mPGES) whereas 
M2 macrophages show up regulation of COX1 and arachidonate 15-lipoxygenase  (Martinez, 
Gordon et al. 2006). 
 
 
Figure 4. Intrinsic metabolism of M1 and M2 polarized macrophages. Figure derived from (Saha, 
Shalova et al. 2017) and reprinted with permission from John Wiley and Sons. 
 
Amino acid metabolism Differences in arginine metabolism are used for long to distinguish 
M1 and M2 polarised macrophages. In M1 macrophages NOS2 expression is increased which 
converts L-arginine into NO and L-citrulline (Fig. 4) whereas in M2 macrophages arginase 1 
is upregulated which metabolizes L-arginine into L-ornithine which serves as a precursor for 
polyamines used in collagen synthesis and cell proliferation during tissue remodelling 
(Biswas and Mantovani 2012, Saha, Shalova et al. 2017). 
Iron metabolism By phagocytosis of red blood cells and setting iron free for erythropoiesis, 
macrophages contribute to iron homeostasis (Soares and Hamza 2016) and iron metabolism in 
M1 and M2 macrophages is dissimilar. The heme group of haemoglobin is catabolized by the 
heme oxygenase-1 (HO-1) enzyme and the iron produced via this process is either excreted 
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from macrophages via FPN1 (Solute carrier family 40 protein) or stored intracellularly by 
ferritin. M2 macrophages show HO-1 induction and high levels of CD163 and CD94, 
responsible for heme uptake and low levels of iron storage (Naito, Takagi et al. 2014). On the 
other side, M1 macrophages show iron retention, supported by low levels of CD163 (Cairo, 
Recalcati et al. 2011). 
Glutathione and redox The intracellular redox status is characteristic for M1 and M2 
macrophages. Reductive macrophages contain high levels of gluthatione and oxidative 
macrophages display low levels of gluthathione (Biswas and Mantovani 2012). In CD4+ T 
cells, a reductive phenotype coincided with production of IL-12 and NO and reduced IL-6 and 
IL-10. Therefore reductive phenotype may support Th1 differentiation (Murata, Shimamura et 
al. 2002).  
In summary, metabolites itself and programming in response to change in the environment 
e.g. nutrients or oxygen, directly influence macrophage functions (O’Neill and Pearce 2016). 
Then, with diabetes pathology in mind, in the next paragraph the literature on the effect of 
hyperglycemia on monocytes/macrophages will be discussed.  
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1.4 Hyperglycemic effect on macrophages  
Information on the effect of glucose on the activation of human primary macrophages is 
limited though animal and in vitro models suggest crucial changes in the biology of these 
immune cells. In THP-1 cells, a human monocytic cell line, high glucose led to increased 
expression of the receptor for oxidized LDL, LOX-1 as well as intracellular ROS and 
enhanced activation of NF-κB and activated protein-1 (AP-1) binding on the LOX-1 gene 
promotor. Overexpression of LOX-1 on monocyte-derived macrophage from T2D support the 
relevance of this gene in diabetic atherosclerosis (Li, Sawamura et al. 2004). Inflammatory 
effects of hyperglycemia are at least partly mediated via TLR activation as inhibition of high 
glucose induced TLR expression led to significant decreases in cytokine release in THP-1 
cells as well as primary human monocytes. PKC signalling as well as p47Phox, essential 
component of the NADPH oxidase production, are proximal in HG-induced TLR2 and TLR4 
activation (Dasu, Devaraj et al. 2008). Increased TLR mRNA and protein, and downstream 
MyD88 signalling has also been found in monocytes from T2D patients together with 
elevated proinflammatory mediators and TLR ligands in the serum compared to controls 
(Dasu, Devaraj et al. 2010). On a functional level, high glucose induced in THP-1 cells 
increased monocyte activation and transmigration (Nandy, Janardhanan et al. 2011). In 
primary human macrophages high glucose alone is rendering a mixed M1/M2 cytokine profile 
which can support progression of diabetic vascular complications (Moganti, Li et al. 2016). 
Acute but not long-term TNF-α as well as sustained IL-1β production was found in M1 
macrophages. IL-1Ra normally released by M2, were produced in M0 and M1 in response to 
hyperglycemia (Moganti, Li et al. 2016). Consistent with in vitro results in monocytes of 
prediabetic people exhibited higher levels of inflammatory CD11c+ and lower content of 
CD206+ compared to controls. This was associated with obesity, IR, triglyceridemia and low 
serum levels of IL-10. Increased iNOS expression levels as well as Arg-1 reduction suggest 
that glucose alone is inducing M1 polarization (Torres-Castro, Arroyo-Camarena et al. 2016). 
Both studies suggest that glucose renders monocytes/macrophages pro-inflammatory. 
FFAs, elevated glucose levels, and oligomers of islet amyloid polypeptide are reported to 
activate the NOD-like receptor family, pYRIN domain-containing 3 (NLRP3) inflammasome 
pathway (Masters et al., 2011). Activation of NLRP3 leads to caspase-1 expression and 
secretion of IL-1β, which mediate decreased insulin sensitivity. IL-1β blocks insulin 
signalling in target cells through activation of inflammatory signalling and the production of 
Suppressor of cytokine signalling (SOCS) proteins. In addition, IL-1β triggers cytotoxicity 
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and death of β cells in the pancreas. Mice genetically deficient for NLRP3, caspase-1, and IL-
1β provided strong evidence for the role of the NLRP3 inflammasome pathway in the 
development of insulin resistance and diabetes (Masters et al., 2011). 
Recently, we showed that in vitro hyperglycemia induces expression of pro-inflammatory 
chemokines and cytokines in primary human macrophages (Moganti, Li et al. 2017). This 
suggests that the negative impact of hyperglycemia on microvascular complications extents to 
its direct influence on immune cells too and thus on the interaction between ECs and 
monocytes. Hyperglycemia causes an immediate but transient production of TNF-α while it 
constitutively causes IL-1β release in human primary monocyte derived macrophages 
(Moganti, Li et al. 2017). In hyperglycemic conditions, macrophages had undergone M1-like 
polarisation.e. proinflammatory phenotype, with increased expression of CD11c and nitric 
oxide synthase while arginase-1 and interleukin IL-10 were down regulated (Torres-Castro, 
Arroyo-Camarena et al. 2016). 
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1.5 Epigenetic programming of macrophages 
Epigenetic processes in monocytes and macrophages regulate transcriptional profile of the 
cells and their responses to stimuli and environmental changes. The epigenetic regulation 
without changing the DNA itself equips the cells with the plasticity they need for the diverse 
tasks in different tissues. Chromatin structure largely impacts the regulation of gene 
expression by altering accessibility to transcription factors, although it is not completely 
resolved how individual epigenetic marks are set up, maintained and influence chromatin 
structure. The major epigenetic mechanisms i.e. DNA-methylation, histone modifications and 
non-coding RNAs will be discussed here.  
Dense DNA-methylation on cytosine’s of CpG dinucleotides, predominantly concentrated in 
CG-islands (CGI), is associated with silencing of promoters (Deaton and Bird 2011). The 
level of DNA methylation is determined by the local activity of DNA methyltransferases 
(DNMT), DNA demethylases as well as the DNA replication rate (Jeltsch and Jurkowska 
2014, van der Wijst, Venkiteswaran et al. 2015). DNA methylation is actively modified in 
different tissues during differentiation (Barres, Yan et al. 2012, Kirchner, Osler et al. 2013). 
Demethylation controls a specific fractions of genes involved in actin cytoskeleton regulation, 
innate immune system and phagocytosis in human monocytes (Wallner, Schröder et al. 2016). 
Methylated CpGs guide transcription factor binding for example transcription factor KLF2, -
4, -5 bind in methylation dependent manner (Liu, Olanrewaju et al. 2014, Rothbart and Strahl 
2014). An upregulation was observed of DNMT1 and 3a in M2 compared to M1 macrophages 
which directed silencing of specific genes (Kittan, Allen et al. 2013). DNMT3b in ATMs 
stimulated was enhanced by stimulation with fatty acids, leading to DNA methylation at the 
PPARγ1 promoter (Yang, Wang et al. 2014) whereas a combined treatment of DNMT 
inhibitor 5-Aza 2-deoxycytidine and HDAC inhibitor Trichostatin A, in treatment of acute 
lung injury during sepsis, showed a protective effect by decreasing the number of M1 versus 
M2 macrophages in the lung tissue (Thangavel, Samanta et al. 2015). Still, little is known 
about active demethylation in macrophages. Ten-eleven Translocation (TET) enzymes are 
essential for DNA demethylation in primary monocytes (Klug, Schmidhofer et al. 2013) 
though this occurs very early during initial 6-18h of the differentiation process (Wallner, 
Schröder et al. 2016).  
Many posttranslational modifications to distinct amino acids of the histone tail have been 
discovered of which methylation and acetylation are most studied. From other modifications 
i.e. citrullination, ubiquitination, sumoylation, ADP-ribosylation, proline isomerization and 
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phosphorylation at different residues among others, the associated function is not completely 
known yet (Rothbart and Strahl 2014). Besides direct physical effect such as positively 
charged lysine acetylation, histone code can mediate indirectly effect on chromatin structure 
by selective recruitment of facilitory proteins. The combination of histone modifications 
and/or cooperation with DNA methylation increase the diversity of histone function (Rothbart 
and Strahl 2014). Histone code is mediated by epigenetic regulators. Epigenetic regulators can 
be divided in three groups based on their function; writers and erasers that mediate and 
respectively remove the marks which are consequently read by readers thereby altering the 
epigenetic status of enhancers and promotor (Hoeksema and de Winther 2016). Histone 
methylation for example is controlled by histone methyltransferases (HMT) and demethylases 
(HDM), which consists of the LSD and JMJC family of enzymes. H3K4me at the 
transcription start site (TSS) is generally associated with transcriptional activation whereas 
H3K9me2/3 and H3K27me3 with gene silencing (Bannister and Kouzarides 2011). H3K4me3 
and H3K27me3 at promoters of macrophage-differentiation related transcription factors 
controls monocyte to macrophage differentiation (Zheng, Wang et al. 2017). However 
combinations of repressive and active marks can exist next to each other and silence 
developmental genes keeping cells poised for activation (Bernstein, Mikkelsen et al. 2006). 
Enzymes that catalyse the addition of methyl groups either belong to the SET-domain 
containing family of proteins, DOT1-like proteins or N-methyltransferases which specifically 
methylate arginine residues (Greer and Shi 2012). HMTs involved in inflammatory signalling 
in macrophages include MLL1, MLL4, Ash11, SET7, SMyd2, Setdb2, Suv39h2, G9a Ezh1 
and 2 and SMYD5. Also, HDMs modulate macrophage polarisation by removing repressive 
marks e.g. on the histone tails of H3K9, H3K36 and H3K27 (Kapellos and Iqbal 2016). The 
most extensively studied HDM being H3K27 specific demethylase JMJD3, which drives 
expression of inflammatory genes in response to LPS (De Santa, Narang et al. 2009) and 
drives IL-12 expression in M1 macrophages during diabetic wound healing (Gallagher, Joshi 
et al. 2015, Kapellos and Iqbal 2016). Another key histone modification to regulate gene 
expression is acetylation. Acetylation of histones is achieved by histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). Acetylation, irrespective of the residue, is in 
general associated with open chromatin and active transcription (Barski, Cuddapah et al. 
2007). Several members of HATs including p300, CBP and PCAF regulate NF-κB mediated 
gene expression in macrophages and their inhibition manifests in anti-inflammatory effects. 
HDACs in macrophages regulate TLR pathways and inflammatory cytokine production for 
example, by recruiting interferon regulator factor (IRF) and Rel family transcription factors to 
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TLR-target genes; HDAC inhibitor trichostatin A targeted LPS-inducible expression of IL-6 
and IFNβ, but not IL-1β in human primary macrophages (Bode, Schroder et al. 2007). 
Therefore, histone code is inducible by the inflammatory factors including bacteria and 
cytokines.  
miRNA are a class of 19–24 nucleotide long non-coding RNAs, that fine tune gene 
transcription i.e. by controlling the stability of targeted mRNAs and/or inhibiting their protein 
translation but also controlling transcription factor expression. Different miRNAs have been 
involved in polarisation of development, polarisation and function of macrophage (Roy 2016). 
Macrophages in turn secrete microvesicles containing miRNAs thereby exerting effects on 
target cells (Roy 2016). and RNAs which exclusively associate with certain argonaut proteins, 
have been shown to mediate epigenetic modifications of DNA and histones (Morris 2009, 
Loscalzo and Handy 2014). miRNA-seq profiling of primary mouse BMDM revealed 31 
miRNAs that regulate macrophage polarization. High expression levels of miR-155, miR-9, 
miR-146a and miR-19 were found in M1- compared to miR-26a-2-3p and let-7c in M2-
polarized macrophages whereas 29 of them specifically target C2H2 zinc-finger genes (Lu, 
McCurdy et al. 2016). Some have been used as therapeutic targets in the study of diabetes. 
For example, anta-miR155, a potent promoter of M1 polarization, delivered into macrophages 
via phagocytosis, reduced inflammation and restored the cardiac function in a mice model for 
diabetic cardiomyopathy (Jia, Chen et al. 2017). Also, anti-miR33 treatment, which 
negatively regulates reverse cholesterol transport factors ABCA1 and HDL, reduced M1-
related genes IL-1B, TNFA, NOS2 and increased anti-inflammatory M2 related genes YM1, 
CD206 in atherosclerotic plaque macrophages of diabetic mice (Distel, Barrett et al. 2014). 
Deletion of microRNA-generating enzyme dicer in macrophages, accelerated atherosclerosis 
in Apoe-/- mice decreased the expression of genes that enhance mitochondrial function, fatty 
acid oxidation, and oxidative phosphorylation via miR-10a and let-7b and miR-195a, 
suggesting that dicer promotes metabolic reprogramming of AAMs (Wei, Corbalán-Campos 
et al. 2018).  
Recent studies point out memory properties for not only the adaptive immune system but also 
for innate immune cells e.g. training vs tolerance (Netea 2013). The role of histone 
modifications involved in macrophage trained immunity was revealed recently (Saeed, 
Quintin et al. 2014). Endogenous stimuli from the diabetic environment, such as glucose and 
advanced glycation end products (AGEs), through epigenetic changes could contribute to 
reprogramming of monocytes/macrophages and this can already occur in the bone marrow 
(El-Osta 2012, van Diepen, Thiem et al. 2016). Current research about the role of glycemic 
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memory in development of diabetic complications later in life, has focused mostly on cells of 
the vascular system i.e. endothelial cells and/or mesengial cells (Brasacchio, Okabe et al. 
2009). Therefore a relevant open question is the effect of hyperglycemia on the epigenetic 
programming of monocytes and macrophages leading to the expression of genes related to 
diabetes pathology.  
 
1.6 The effect of hyperglycemia on the transcriptional profile of human primary 
macrophages and expression of S100 family 
The effect of hyperglycemia on the transcriptional profile of human primary macrophages has 
been identified previously using Affymetrix gene expression profiling technology and was 
published elsewhere GSE86298 (Moganti 2017). GSEA/KEGG analysis was done to examine 
pathways enriched in gene sets with a significant difference in expression between 
hyperglycemic cells compared to controls. The Affymetrix gene expression profiling revealed 
that several members of the S100 family of proteins to be up regulated by culture under high 
glucose conditions. In M0 as well as M1 macrophages it was found that gene expression of 
S100A9 and S100A12 were highest up regulated in hyperglycemic condition in M1 
macrophages and S100A8 in M0 macrophages (Table 1).  S100A8 and S100A9 are part of the 
IL-17 signaling (KEGG) pathway. Other members of the pathway which are significantly up 
regulated include MAPK3, CHUK, HSP90AB1, CASP8, CXCL3, LCN2 for M0 and HSP90B1, 
MAPK3, IL1B, FOS, MAPK14, TRAF3, TNFAIP3, MAPK9, IL17F, MAPK13, RELA, CXCL5 
for M1 macrophages. 
 
Table 1. Differential expression of S100 family members identified by Affymetrix chip 
technology 
GeneSymbol 
Fold 
change  
NS 
Fold 
change 
IFNγ 
Fold 
change  
IL-4 
Adjusted 
p-Value 
for 
Estimate 
of NS 
Adjusted 
p-Value 
for 
Estimate 
of IFNγ 
Adjusted 
p-Value 
for 
Estimate 
of IL-4 
S100A12 1,309409 4,411155 1,055020 0,368051 0,000035* 0,973707 
S100A10 1,080588 1,287492 1,157048 0,478160 0,008734* 0,421370 
S100Z 1,132830 1,658848 1,089954 0,674781 0,024781* 0,929235 
S100A4 1,051011 1,970927 1,017411 0,894199 0,004853* 0,993473 
S100A9 1,435917 2,130770 1,019306 0,073179 0,000687* 0,990445 
S100A16 1,954496 1,004997 2,022121 0,020164* 0,990636 0,088720 
S100A7L2 1,106120 1,023489 1,049944 0,029907* 0,677327 0,644794 
S100A8 3,193302 1,865075 1,380401 0,003648* 0,066537 0,728683 
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*Every comparison is between cells cultured in high glucose conditions versus cells cultured 
in normal glucose conditions 
 
Plasma levels of inflammatory proteins revealed new markers for prediabetes as well as T2D. 
These included EN-RAGE (S100A12) as well as IL-17 (Mac-Marcjanek, Zieleniak et al. 
2018). Macrophage are important in T1D onset and progression together with T and B 
lymphocytes (Kopan, Tucker et al. 2018). B-cells bind antigens directly whereas T cells need 
antigen presenting. Macrophages are weak APCs compared to dendritic cells but can sustain 
activation and differentiation of primed T lymphocytes (Geissmann, Gordon et al. 2010). 
After initial priming, polarizing cytokines determine T helper cell differentiation. S100 
proteins can induce Th17 cells (Reinhardt, Foell et al. 2014), and IL-17 and Th17 cells do 
play an important role in pathogenesis of diabetes (Abdel-Moneim, Bakery et al. 2018). S100 
genes are mainly expressed in myeloid cells (Donato, Cannon et al. 2013). They are 
differentially expressed in neutrophils compared to macrophages and dendritic cells (Averill, 
Barnhart et al. 2011). S100 proteins act upon changes in intracellular Ca
2+
 levels and are 
found to play a role in inflammatory diseases, where they are used as diagnostic marker, and 
cancer (Leach, Yang et al. 2007, Bresnick, Weber et al. 2015). Expression levels of S100A8, -
A9 (Bouma, Coppens et al. 2005, Jin, Sharma et al. 2013) and circulating levels (Ortega, 
Sabater et al. 2012, Cotoi, Dunér et al. 2014) of S100A12 (ENRAGE) and soluble RAGE 
(Basta, Sironi et al. 2006, Dong, Shi et al. 2015) are positively related to diabetes pathology. 
Taking into account that they are pro-inflammatory molecules and can be significantly 
implicated in diabetes development and progression, we examined the regulation of 
expression of S100 proteins by glucose and glucose programming in human primary 
macrophages.  
1.7 Aims 
The goal of the study was to investigate the mechanisms of hyperglycemia-mediated 
programming of macrophage functions supporting diabetes progression. S100A9 and 
S100A12 have been selected as reference genes due to the role in the activation of endothelial 
cells and elevated expression levels in the circulation of diabetic patients. 
 
The specific aims included: 
 To investigate the regulation of S100A9 and S100A12 expression during the 
macrophage differentiation in normal and hyperglycemic conditions 
 To analyse the expression of S100A9 and S100A12 in monocytes of diabetic patients  
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 To examine the effect of hyperglycemia on the histone code modifications on the 
promoters of S100A9 and S100A12 in human macrophages 
 To examine the involvement of histone modifying enzymes in the regulation of  
S100A9 and S100A12 expression  
 To examine potential memory for the expression of S100A9 and S100A12 compared 
 and CCR2 
 To examine whether hyperglycemia sensitizes macrophages to respond to pro-
inflammatory exogenous and endogenous factors by  induction of S100A9 and 
S100A12 gene expression 
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2 MATERIALS & METHODS 
2.1 Chemicals, reagents and kits 
Table 2. Chemicals, reagents and kits. 
Product  Company  
0.05% Trypsin/EDTA solution  Biochrom  
10x Earle’s Balanced Salt Solution (EBSS)  Sigma Aldrich  
10x Incomplete PCR buffer  BIORON  
30% Acrylamide/Bis Solution  Bio-rad  
4',6-diamidino-2-phenylindole (DAPI)  Roche Diagnostics  
50x Tris-Acetate EDTA (TAE) buffer  Eppendorf  
Acetic acid  Merck  
Agarose  Bioron  
Amersham Hyperfilm ECL  GE Healthcare  
Ammonium persulfate (APS)  Merck Millipore  
Ampicillin  Sigma Aldrich  
BL21-(DE3)-RIL-Codon-Plus E.coli  Stratagene  
Bovine Serum Albumin (BSA)  Sigma Aldrich  
BSA loading controls  Bio Rad  
CD14 MicroBeads  Miltenyi Biotec  
Dako Pen  Dako  
Dako Fluorescent Mounting Medium  Dako  
Deoxyribonucleotides (dNTPs) 10M  Fermentas  
DEPC Water  Thermo Fisher Scientific  
Dexamethasone  Sigma Aldrich  
Dimethylsulfoxide (DMSO)  Sigma Aldrich  
DMEM medium+Gluta MAX  Thermo Fisher Scientific  
DMSO  Sigma Aldrich  
DNA ladder  Thermo Fisher Scientific  
DNA Loading Dye (6x)  Thermo Fisher Scientific  
DNase Buffer (10x)  Thermo Fisher Scientific  
DNase I RNase free 1U/μl solution  Fermentas  
DRAQ5  Cell Signaling  
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EDTA  Invitrogen  
EDTA-free Protease Inhibitor Cocktail Tablets  Roche  
Ethanol  Roth  
Fetal calf serum (FCS)  Biochrom  
Gel Blue stain reagent  Pierce  
Gel Red  Biotium  
Glycerol  Sigma Aldrich  
Isopropanol  Merck Millipore  
Laemmli sample buffer  Bio Rad  
Methanol  Merck  
Nitrocellulose blotting membrane  GE Healthcare  
Non-Fat Dry Milk  Bio Rad  
Oligo(dt) primer  Thermo Fisher Scientific  
Page Ruler Plus Prestained Protein Ladder (10-250 kD)  Thermo Fisher Scientific 
Paraformaldehyde (PFA)  Sigma Aldrich  
1X Phosphate buffered saline (D-PBS), sterile 1x  Biochrom 
PCR primers  Eurofins MWG Operon  
PCR probes  Eurofins MWG Operon  
Penicillin/Streptomycin  Biochrom  
Percoll  GE Healthcare Life Sciences  
Ponceau S solution  Sigma Aldrich  
Recombinant human MCP-1 (CCL2)  Prepotech  
Recombinant Human IL-4  Peprotech  
Recombinant human M-CSF  Peprotech  
RPMI medium  Life Technologies  
Sensimix II Probe Kit  Bioline  
Sodium Chloride  Sigma Aldrich  
Sodium dodecyl sulfate (SDS) 10%  Bio-Rad  
TEMED  Roth  
TGS (Tris/Glycine/SDS) buffer 10x  Bio-Rad  
Tris-HCl buffer 0.5M, pH 8.8  Bio-Rad  
Tris-HCl buffer 1.5M, pH 6.8  Bio-Rad  
Triton X-100  Sigma Aldrich  
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Trypan blue solution  Sigma Aldrich  
Tween 20  Sigma Aldrich  
β-mercaptoethanol  Sigma Aldrich  
Luminata Forte Western HRP substrate Millipore 
  
 
2.2 Consumables 
Table 3. Consumables. 
Product  Company  
0.22 μm filter  Fisherbrand  
22x22 mm coverslips  Marienfeld  
3MM blotting papers  GE Healthcare  
CASY cups  Omni Life Sciences  
Cryovials  Nunc  
Elisa plate sealers  R&D systems  
Elisa Plates  R&D systems  
GeneChip® Human Gene 2.0 ST Array  Affymetrix  
Glass slides  Servoprax  
LS columns  Miltenyi Biotec  
Parafilm  American National Can  
PCR tubes  Star Labs  
Petri dishes  Nunc  
Pipettes tips  Eppendorf  
Pipettes  Eppendorf  
Plastic wrap  Toppits  
Western film  GE Healthcare  
Safe-Lock Eppendorf Tubes, 1.5 ml  Eppendorf  
Scalpel  Feather  
Sterile pipette tips  Star Labs, Nerbeplus  
Tubes  Falcon  
Trans-well 5 μm  Corning  
Medical X-ray film Typon Röntgen-film GmbH 
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2.3 Equipment 
Table 4. Equipment. 
Product  Company  
Agarose electrophoresis unit  VWR  
Autoclave VX-95  Systec  
Balance  Kern  
Bioruptor Diagenode 
CASY Cell Counter  Schärfe System  
Cell culture hood  Thermo Fisher Scientific  
Cell culture incubator  Heraeus Instruments  
Centrifuge 5415 D  Eppendorf  
Centrifuge 5804 R  Eppendorf  
Confocal laser scanning microscope SP8  Leica Microsystems  
Electrophoresis comb  Peqlab  
Electrophoresis power supply  Peqlab  
FACS Canto II  BD Biosciences  
Freezer (-20°C)  Liebherr  
Freezer (-80°C)  Sanyo  
Fridge (4°C)  Liebherr  
Ice machine AF100  Scotsman  
Inverted microscope  Leica Microsystems  
LightCycler 480 Instrument  Roche Diagnostics  
MACS manual cell separator  Miltenyi Biotec  
Gel dryer model 583  Bio-Rad  
Magnetic stirrer MR3000  Heidolph  
Microwave oven  Sharp  
Neubauer haemocytometer  Assistent  
Pipette Controller  Accu Jet Pro, Brand  
Roller  Ortho Diagnostic Systems  
Rotator  Neolab  
SDS-PAGE chamber  Peqlab  
SDS-PAGE gel comb  Peqlab  
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SDS-PAGE power unit Power-Pac 200  Bio-Rad  
SDS-PAGE unit  Biometra  
Shaker KS 260 basic  IKA  
Sorvall RC5C Plus ultracentrifuge  Thermo Fisher Scientific  
Staining Dish  Neolab  
Staining rack  Neolab  
Tecan Infinite 200  Tecan  
Thermomixer 5436  Eppendorf  
Thermomixer comfort  Eppendorf  
Tweezers  Neolab  
Ultracentrifuge tubes 50 ml  Thermo Fisher Scientific  
UV fluorescent light  Peqlab  
Vortex Genie 2  Scientific Industries  
Water bath  Memmert  
Water bath VWB12  VWR  
X-ray cassette  Kodak  
X-ray film processor CAWOMEN 2000 IR  CAWO Solutions  
 
2.4 Kits 
Table 5. Kits used in the study. 
Kit  Company 
E.Z.N.A. Total RNA Kit I  
 
Omega bio-tek 
DNeasy Blood & Tissue Kit Qiagen 
QIAquick PCR Purification Kit  Qiagen 
RevertAid H Minus First Strand Synthesis Kit  Fermentas 
SimpleChIP® Enzymatic Chromatin IP Kit  Cell Signaling Technology 
Pierce™ BCA Protein Assay Kit  Thermo Scientific 
 
2.5 Cell culture 
2.5.1 Monocyte isolation and generation of macrophages  
Human monocytes were isolated from buffy coats from individual donors as described 
(Kzhyshkowska, Gratchev et al. 2004) with modifications. Buffy coats were provided by the 
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German Red Cross Blood Service Baden-Württemberg – Hessen. Buffy coats were obtained 
from healthy donors after informed consent. Buffy coats were diluted 1x with Ca2+- and 
Mg2+- free phosphate-buffered saline (PBS) (Biochrom). A volume of 25 ml then was 
layered on top of a 15 ml Ficoll gradient (Biochrom) in a 50 ml falcon tube. Peripheral blood 
mononuclear cells (PBMCs) were collected from the interphase and washed three times with 
PBS. PBMCs were further purified using a PercollTM gradient. Ficoll and Percoll gradients 
were centrifuged at 420 g for 30 minutes at RT without brakes. The cells obtained were 
subjected to CD14+ magnetic cells sorting (Milteny Biotech). For the culture, CD14+ 
Monocytes were resuspended in SFM serum-free medium supplemented with 5mM 
(normoglycemia, NG) or 25 mM glucose (hyperglycemia, HG) at a concentration of 1x10
6 
cells/ml. Cells were incubated with cytokines derived from TEBU Peprotech in the presence 
of 7.5% CO2 for 6 days. 5ng/ml MCSF and 100ng/ml interferon-gamma (IFNγ) was used to 
induce M1 macrophage polarization and MCF with 10ng/ml IL-4 to induce M2 macrophage 
polarization.  
2.5.2 Collecting of conditioned medium  
Conditioned medium as collected on day 1, day 3 and day 6. The samples were stored at -
80°C until further use. Human S100A9 and S100A12 were detected using and ELISA kit 
(DY5578, and DY1052-05, R&D systems) according to the manufacturer’s instructions. 
Concentration was calculated by regression analysis of a standard curve. 
2.5.3 Viability Assay 
Alamar blue solution (Life technologies, Germany) was added to the medium (10% of total 
volume) and the cells were incubated in the presence of 7.5% CO2 at 37°C for 3h. 
Fluorescence was measured in triplicates at 590 nm read by Tecan Infinite® 200. 
Fluorescence of pure Alamar Blue was used as a negative control.  
2.5.4 Inhibition of histone modifying enzymes 
Primary human derived macrophages were obtained as previously described. M1 
macrophages which were cultured in the presence of MCSF and IFN-γ under normal and high 
glucose conditions were treated with inhibitors for SET7, SMYD3 and Mixed Lineage 
Leukemia (MLL) histone methyltransferases (HMTs). PFI-2 hydrochloride inhibitor for SET7 
and EPZ031686 inhibitor of SMYD3 where obtained from MedChem Express (US). WDR5 
0103 inhibitor of MLL HMTs was obtained from Bio-techne (US). The inhibitors dissolved in 
DMSO. Following stock concentration have been prepared; EPZ031686 1 mM, PFI-2 0.1 mM 
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and WDR5 0103 10 mM.  Working concentrations are indicated. Corresponding amounts of 
DMSO were used as controls.  Cells were treated with inhibitors from the time of isolation on 
up to 6 days followed by RNA isolation. The sets of donors used for application of different 
inhibitors partially overlap but are not identical due to technical reasons. 
2.5.5 Immunofluorescence staining 
Monocyte derived macrophages were stimulated with MCSF and INF-γ and cultured on cover 
glasses (Neolab, Germany) for 6 days under normal and high glucose conditions. All further 
procedures have been performed at RT. Cells were fixed using 2% PFA for 10 minutes, 
followed by incubation with 0.5 % TritonX-100/PBS 15 minutes for permeabilisation, and 
finally fixed with 4% PFA 10 minutes. Plates were washed 2 times with PBS for 5 minutes on 
shaker and one time with PBS 1x / 0.1% Tween20 for 30 seconds. Blocking was done with 
3% BSA/PBS for 1 hour at RT. After washing one more time with PBS 1x /0.1% Tween20, 
30 seconds primary antibodies were applied diluted in 1% BSA/PBS. Following antibodies 
were used:  SET7/SET9 (#2813 - Cell Signaling, stock 35.3 µg/ml, used in 1:25 dilution) and 
Rabbit IgG #2729 - Cell Signaling, stock 1 mg/ml) used in same concentration as a negative 
control, were incubated for 1.5 hour in a humid chamber. Cells were washed 3 times with 
PBS for 5 minutes on shaker and one time with PBS 1x /0.1% Tween20, 30 seconds. 
Secondary antibodies diluted in 1% BSA/PBS Donkey-α Rabbit IgG Cy3 (#711-165-152 – 
Dianova, 1:400) and DRAQ5 (#4084L - Cell Signalling, 1:1000) for nuclear staining and 
incubated for 45 minutes After washing 4 times for 5 minutes with PBS, slides were mounted 
with Fluorescent mounting media (Dako) and kept at 4°C. Expression and localization was 
analysed using the Leica TCS SP8 confocal laser scanning microscope. 
2.6 RNA-related methods 
2.6.1 Isolation of total RNA  
Cells were lysed in TRK lysis buffer, and RNA was isolated using E.Z.N.A. Total RNA kit 
according to the manufacturer’s instructions (Omega Bio-tek). A working solution of TRK 
Lysis Buffer was made prior to starting by mixing 20 µl of ß-mercaptoethanol per 1 ml of 
TRK Lysis Buffer. 3x10
6
-1x10
7
 cells were disrupted by adding 350 µl of TRK Lysis Buffer. 
The cells were homogenized by passing the lysate 10-15 times through a needle fitted with a 
syringe. An equal volume of 70% ethanol was added to the lysate. Each sample was vortexed 
and applied to a HiBind RNA spin column placed into a 2 ml collection tube. The column was 
centrifuged at 10,000 g for 1 minute. The flow-through was discarded, and the column was 
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washed once with 500 μl of RNA wash buffer I and two times with 500 μl of RNA wash 
buffer II. After the last centrifugation, the column was placed in a 1.5 ml RNAse-free 
Eppendorf tube. The RNA was eluted with 40 μl of RNase-free water preheated at 70°C at 
maximum speed for 1 minutes The concentration of isolated RNA was determined with a 
Tecan Infinite® 200. The quality of the obtained RNA samples was analysed on 1% agarose 
gel. Isolated samples were stored at -80°C until use. 
2.6.2 cDNA synthesis 
cDNA synthesis was performed using RevertAid RT Reverse Transcription Kit (Thermo 
Scientific) with oligo-dT primers according to the manufacturer’s instructions. Shortly, 5 µl 
RNA was digested with 1 µl of DNase, 1 µl of DNase buffer 10X and 3µl of H2O at 37°C for 
40 min and followed by inactivation of the enzyme at 70°C. After digestion, 1 μl of Oligo dT 
primer and 1µl of H2O was added to the above RNA sample.  Annealing of the primer was 
done at 70°C for 5 minutes and the samples were placed on ice.  
4 µl of Reaction Buffer 5x, 1µl Ribolock RNase inhibitor, 2µl of dNTP Mix(10M) and 1µl of 
Reverse transcriptase was added to the above sample and incubated at 42
o
C for 1 hour and 
activity of the enzyme was stopped by an additional incubation at 70°C for 10 minutes. The 
obtained cDNA was diluted 1:10 with double distilled water and 1µl was used for RT-PCR. 
2.6.3 Real-time PCR Taqman 
Primers and probes were obtained from Eurofins (Germany). Dual-labelled probes were used 
containing FAM on the 5’ end and a BHQ1 quencher at the 3’ end of the sequence. A list of 
designed primers used in experiments is shown in Table 6. Primer sequences are shown from 
the 5’ end to 3’ end direction. For normalization 18SrRNA was used as a reference gene. Use 
of 18S was validated compared to other housekeeping genes (not shown). Taqman ready to 
use Human primers for S100A9 (Hs00610058_m1), S100A12 (Hs00942835_g1), ARRDC4 
(Hs00411771_m1) and CCL24 (Hs00171082_m1) were obtained from ThermoFisher 
Scientific. Primers for IL1B, CCR2 and 18SRNA were designed. 
 
Table 6. Primers used to determine mRNA expression by RT-PCR. 
Gene Primer Sequence (written 5' - 3') 
CCR2 Forward GACCAGGAAAGAATGTGAAAGTGA 
CCR2 Reverse GCTCTGCCAATTGACTTTCCT 
CCR2 Probe CACAAGGACTCCTCGATGGTCGTGG 
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IL-1B Forward ACAGATGAAGTGCTCCTTCCA 
IL-1B Reverse GTCGGAGATTCGTAGCTGGAT 
IL-1B Probe CTCTGCCCTCTGGATGGCGG 
18S rRNA Forward CCATTCGAACGTCTGCCCTAT 
18S rRNA Reverse TCACCCGTGGTCACCATG 
18S rRNA Probe ACTTTCGATGGTAGTCGCCGTGCCT 
2.6.4 Primer design and optimization 
GenScript Real-time PCR (TaqMan) online Primer Design tool was used to design primers 
and probes for your Real-time PCR experiments. PCR amplicon's size range of ideally 100-
200bp and primer Tm (melting temperature) between 52-60°C and probe Tm 62-70°C and an 
optimum CG content of 50%. A primer matrix (Table 7) with the forward and reverse primers 
was used to determine the optimal primer concentrations for RT-PCR which gives the lowest 
threshold cycle (Ct) and maximum reporter minus baseline signal. Primer optimization was 
performed with a fixed probe concentration of 250 nM. After the primers were optimized, 
probe optimization was performed with the following concentrations: 50nM, 100nM, 150nM, 
200nM and 250nM. The primer and probe combination that yielded optimal assay 
performance was chosen for further experiments.  
 
Table 7.  Matrix for primer concentrations. 
 
 
 
 
 
 
 
 
 
 
 
A PCR reaction mix was prepared as described (Table 8) and amplification was performed 
using PCR reaction program (Table 8) by LightCycler 480 (Roche).  
 
 
 
 
 
Primer Design Matrix  
 Forward Primer (nM) 
Reverse Primer (nM) 
 50 300 900 
50 50/50 300/50 50/900 
300 50/300 300/300 300/900 
900 50/900 300/900 900/900 
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Table 8. PCR reaction mix 
Reagent Volume for 1 PCR reaction (10 µl) 
TaqMan Gene Expression Master Mix  5 μl  
TaqMan primer mix (target)  0.5 μl  
TaqMan primer mix (reference)  0.5 μl  
cDNA  1 μl  
Distilled water  3 μl  
 
Table 9. PCR reaction program. 
  Temperature Time 
a. Initial denaturation 95°C 3 minutes 
b. Denature 95°C 10 seconds 
c. Anneal and extension 60°C 30 seconds 
d. Repeat steps a. and b. for a total of 50 cycles   
 
2.7 Protein techniques 
2.7.1 Western blot 
Whole cell lysates of macrophages were collected by plating the cells on ice and taking the 
medium to collect also the floating cell. 50 µl of 2x Laemmli buffer supplemented with 2% ß-
mercaptoethanol was added per 1x10
6
 cells and cells were collected together with the cells in 
the medium. Protein concentrations were measured by Pierce™ BCA Protein Assay kit. 
Samples where heated for 2-3 minutes at 95
o
C, and 10 µg of protein was used for loading on 
the gel.  
A 15 % separation gel was prepared according to Table 10 and poured between the two glass 
plates to cover 80 % of the unit. Isopropanol was added on top and the separation gel was left 
to polymerize until it was solid. A stacking gel was prepared according to Table 10 and 
poured on top of the separation gel. A comb was inserted into the stacking gel to form loading 
wells. The gel was left to polymerize until it was solid. The gel casting unit was transferred to 
the electrophoresis unit and filled with 1x TGS running buffer. 5 μl of PageRuler™ Plus 
Prestained Protein Ladder (#26619, Thermo scientific) was pipetted into the first well. 
Electrophoresis was performed at a constant current of 20 mA for 1 gel and 40 mA for 2 gels.  
The gel was placed in a plastic container filled with blotting buffer. Filter papers and a 
nitrocellulose membrane were cut to the gel size. The Western Blot cassette was arranged in 
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the following order: Spongy pad/ 2x Whatmanpaper / gel/ nitrocellulose blotting membrane 
0.2 µm / 2x Whatmanpaper / Spongy pad. The cassette was placed in the blotting device, 
which filled with blotting buffer. The blotting was done at a constant current of 150 mA 
overnight. The membrane was washed in a plastic container with PBS and then stained with 
Ponceau S solution for 10 min to visualize the protein bands. The membrane was washed and 
replaced into blocking buffer 6% Blotting Grade Blocker non-fat dry milk in PBS and then 
incubated for 1 hour. The membrane was further incubated with primary antibody diluted in 
1% non-fat milk/PBS on a shaker for 3 hours at RT or O/N at 4 degrees. The membrane was 
washed 4 times for 5 minutes with 0.1% Tween 20/PBS on a shaker. The membrane was then 
incubated with the secondary antibody diluted in 1% milk/PBS for 45 minutes at RT on a 
shaker. The membrane was washed 4 times for 10 minutes with 0.1% Tween 20/PBS on a 
shaker. 2 ml western HRP development solution was added to cover the membrane, and the 
membrane was incubated for 2 minutes The X-ray film was developed with the CAWOMAT 
2000 IR film processor.  
 
Table 10. Buffer preparation for Western Blotting. 
Components Volume (ml) 
Lysis buffer  For 100 ml with ddH2O 
1M Tris ph7,4 5 
NaCl 5 M 3  
10% NP-40 solution  10 
 10% Sodium Deoxycholate  2,5 
0,5 M EDTA (Gibco) 0,2  
Use fresh 10 ml lysis buffer + Protease inhibitor cocktail 
  
Blotting-buffer= „Towbin-Puffer“ For 1L 
ddH2O  700  
Methanol 200  
10x TGS 100   
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Table 11. Preparation of gels. 
Components Separation gel 15% 
For 25 ml 
Stacking gel 
For 10 ml 
H2O 5,57 6,8 
30% Acrylamide mix 12,5 1,7 
1,5 M Tris (pH 8.8) 6,25 1,25 
10% SDS 0,25 0,1 
10% APS 0,25 0,1 
TEMED 0,01 0,01 
 
Table 12. Antibodies used for Western Blotting. 
Antibody Company CatNr Dilution 
Anti-S100A8 R&D MAB4570 1:250 
Anti-S100A9 R&D AF5578 1:1000 
Anti-S100A12 R&D AF1052 1:200 
Anti-Β-actin Santa cruz sc47778 1:500 
Anti-mouse HRP Amersham NA931 1:2000 
Anti-sheep HRP R&D HAF016 1:1000 
Anti-goat HRP R&D HAF017 1:1000 
 
2.7.2 Flow cytometry 
Frozen PBMCs of healthy controls and diabetic individuals, were resurrected and plated in 
RPMI+10% FCS+1% P/S and incubated overnight at 37°C, with the diabetic group consisting 
of patients with severe complications, consisting of nephropathy and additional patients with 
nephropathy and cardiovascular disease. The next day, the cells were harvested and washed 
with PBS. Fixable viability dye (FVD, Thermofisher) was added to all unstained, IgG control 
and stained FACs tubes and incubated for 30 minutes at 4°C protected from light. Cells were 
washed twice with FACS Buffer (PBS +0.4% BSA +0.02 NaN3). 10 µl FcR Blocking 
Reagent (Miltenyi Biotec) was added to all tubes and incubated for 5 min at RT.  Antibodies 
were added to stained tube and incubated 20 minutes at 4°C in the dark. Cells were washed 
twice with cellwash, resuspended cells in PBS and fixed with 3.5% Formaldehyde while 
vortexing. After 15 minutes at RT in the dark, cells were washed with PBS and resuspended 
in 0.1% Saponin (Roth) and left on ice for 15 minutes. Cells were centrifuged, resuspended in 
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0.1% Saponin. 10 µl FcR block was added and incubated for 5 minutes on ice. For 
intracellular staining antibodies or isotype controls for the critical colours were added to the 
respective tubes and incubated for 30 minutes on ice. Cells were washed twice with 0.1% 
Saponin, resuspended in FACS Buffer and analysed by BD FACS Canto II. 
Antibodies for the following markers were used: HLA-DR, CD3, CD19, CD56, CD16, and 
CD14 (Biolegend). First, cells were selected that were positive for HLA-DR. All cells that 
were positive for CD3, CD19, and CD56 were excluded. Using a scatter plot of CD16 versus 
CD14 monocyte population were separated into classical (CD14+CD16-), non-classical with 
low CD14 expression (CD14-CD16+) and intermediate (CD14+CD16+) monocytes. These 
populations were analysed for the expression S100A9 and S100A12. 
 
Table 13. Antibodies used for flow cytometry. 
Marker Conjugate Control isotype-
matched ab 
Volume per assay 
(µl) 
CD16  APC Na 2,5  
CD3  FITC Na 1 
CD19 FITC Na 1 
CD56 FITC Na 1 
CD14  PerCPCy5.5 Na 1 
HLA-DR  PE Cy7 Na 0.5 
S100A9  PE IgG1, κ 0.5 
S100A12  AF405 IgG2b 5 
na: not applicable 
2.7.3 Enzyme-Linked Immuno Sorbent Assay (ELISA) 
Concentrations of secreted cytokines were analysed in the conditioned medium (also named 
supernatants) of M0, M1 and M2 macrophages cultured under normal and high glucose 
conditions using ELISA assays from R&D systems (Wiesbaden, Germany) according to the 
manufacturer’s instructions. 96 well plates were coated with capture antibody at working 
concentration for overnight incubation. The next day these plates were washed with washing 
buffer (0.05% Tween® 20 in PBS pH: 7.2-7.4) and plates were blocked with Reagent Diluent 
(1% BSA in pH: 7.2-7.4) for 1 hour. After blocking, 50 µl of sample or 100 µl of standards in 
Reagent Diluent was added per well and incubated for 2 hours. After incubation, wells were 
washed 3 times with washing buffer, and 100 μl of detection antibody was added according to 
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the manufacturer’s instructions and incubated for 2 hours. After incubation, wells were 
washed 3 times, and 100 μl of Streptavidin-HRP diluted in Reagent Diluent was added to 
each well and incubated for 20 minutes After incubation, wells were washed 3 times and 
substrate solution was added to each well and incubated for 20 minutes Blue colour 
development was controlled and 50 µl of stop solution (2N H2SO4) was added to stop the 
reaction. Optical density of each well was measured immediately, using a micro plate reader 
(Tecan Infinite® 200) at 450nm.  
 
2.8 Glucose uptake assay 
Glucose uptake was measured by Glucose uptake cell-based assay kit (Cayman chemical, 
USA). Cells were seeded in 96-well plate (black with clear bottom) 1x10
5
 per 100 µl. At day 
six the medium was changed to Zero glucose SFM and incubated at 37
o
 for 2 hours. Ten 
minutes before measurement, 2-NBDG (100-200µg/ml) and/or 100µM WZB117 GLUT1 
inhibitor (Cayman chemical, USA) as a negative control, were added to the cells. Cells were 
kept in dark to prevent bleaching. Cells were washed once with PBS. 100 µl PBS was added 
and glucose uptake was analysed immediately using a micro plate reader (Tecan Infinite® 
200) at a fluorescence intensity of 485/535nm. 
2.9 Chromatin-Immunoprecipitation (ChIP) 
2.9.1 Chromatin isolation. 
ChIP is used to recognize relative abundance of chromatin fractions which contain a specific 
antigen. Specific antibodies are used which recognize a specific protein or histone 
modification of interest and its interaction at one or more locations in the genome. 
ChIP assays were performed with SimpleChIP® Enzymatic Chromatin IP Kit (Cell Signaling 
Technology) according to the manufacturers’ protocol. Cells were fixed and the antigen of 
interest is cross-linked to its chromatin binding site with 1% formaldehyde for 10 minutes at 
RT. Glycine was added for 5 minutes to quench the formaldehyde and terminate the cross-
linking reaction. From every culture dish cells were washed twice with ice-cold PBS scraped 
and taken in 2 ml PBS + 10 µl PIC buffer.  
2.9.2 Immunoprecipitation  
One immunoprecipitation preparation (IP prep) was defined as 5 x 10
6
 cells. Cells were 
washed once in buffer A and nuclei were pelleted and resuspended in buffer B. Chromatin 
was digested with micrococcal nuclease with an optimized ratio of 0.5 µl per IP prep and 
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sonicated 9 cycles with high intensity and ON-OFF intervals (Diagenode UCD-200TM-EX) 
to obtain fragments of 150 to 900 base pairs. For immunoprecipitation digested chromatin 
was diluted into ChIP buffer and 2 µg of DNA and 2 μg of primary antibody (Table 14) was 
used in a final volume of 0.5 ml and incubated at overnight at 4°C with rotation. Normal 
rabbit immunoglobulin G (IgG) was used as a negative control for the pull down and Anti-
histone H3 (D2B12 antibody) was used as a positive controls.  
 
Table 14. Antibodies used for ChiP assay. 
Antibody Company 
Anti-H3K4me1 Abcam (#8895) 
Anti-H3K4me3 Merck Millipore (#07-473) 
Anti-Ace H3 Merck Millipore (#06-599) 
Anti-rabbit IgG Abcam (#27478) 
Anti-Total H3 Cell Signaling (#4620) 
 
2.9.3 Elution of chromatin, reversal of cross-links and DNA purification 
Immune complexes were captured using 30 µl of ChIP Grade Protein G Magnetic Beads. The 
chromatin was eluted, and crosslinks were reversed by adding 6 µl 5M NaCl and 2 µl 
Proteinase K and incubation for 2 hours at 65°C. The DNA was purified using QIAquick PCR 
Purification Kit. The amount of precipitated genomic DNA concentration was measured with 
a Tecan Infinite® 200.  
2.9.4 Quantification of DNA by PCR 
Samples were subjected to RT-PCR using primers for different promoter regions of S100A9, 
S100A12, IL1B and CCR2 (Table 15). 1 µl of DNA was added to each well. PCR reactions 
included a 2% input sample, isotype and total H3 control and one well with no DNA to 
control for contamination. Signals obtained from each immunoprecipitation are expressed as a 
percent of total input chromatin. IP efficiency was calculated with the following equation: 
Percent Input = 2% x 2(CT 2%Input Sample – CT IP Sample). Big differences by inefficient 
washing or contamination result in high background of IgG, when IgG was lower than 0.1% 
of the input control, we considered variation as negligible. Anti-histone H3 (D2B12 antibody) 
was used as a positive control. CT values of the Input-samples were compared between 
normal and high glucose samples. With normalizing to H3 the density of specific chromatin 
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modification to the amount of nucleosomes on promoter was normalised. 3,000 bp upstream of 
the transcription start site (TSS), defined by SwitchGear genomics tool in the Epigenomebrowser.org 
was used to scan for suitable ChIP primers.  
 
Table 15. Primers used for ChIP on the different promoters. 
Gene promoter Region Primer name Sequence 5' - 3' 
S100A9 P1 S100A9 (1) F GCCTGGTGCTAAGACTTTGG 
S100A9 (1) R GCATGACAATGAAGCAGGGT 
S100A9 (1) Pr AGCAGGCAGCATCCCTGCCT 
P2 S100A9 (2) F TGAGCTCTTCCCAACTTTCCA 
S100A9 (2) R CTCACACTGCTGAGATGCAC 
S100A9 (2) Pr ACTGCCTAAGGTCACACAGACAGTCTG 
P3 S100A9 (3) F GCATTACCACACTGCTCACC 
S100A9 (3) R GAGCCACACAGAGTGTTTGC 
S100A9 (3) Pr TGGCCCTTTGGCCCTGTCTC 
P4 S100A9 (4) F TCCGGGTGTCAGTTTCTTCA 
S100A9 (4) R TGCCTGGCTCTGTGATACTTA 
S100A9 (4) Pr TGCAAGAGGGTTGCCCACCTCT 
P5 S100A9 (5) F GCTGTGTGCATAGGAGAAGG 
S100A9 (5) R TCTGGCTCTCAACACTTGCT 
S100A9 (5) Pr TGCCTCTGTCCAACAATTGGCTGTAGA 
S10012 P1 S100A12 (1) F ACAGCCTGAGTGTCTTGTTT 
S100A12 (1) R ACTGATCCTCTGCTCCAGTG 
S100A12 (1) Pr ACCTCCTCCTAAGTCGTTCTGGGATGC 
P2 S100A12 (2) F CCCACACCTGTGAAGATAAGC 
S100A12 (2) R CCCACCCAGGTTGGTTTCTA 
S100A12 (2) Pr ACCAATCTCACAACTTGCCCACAAGGA 
P3 S100A12 (3) F AGGGCTAAGATGAAGCCTGA 
S100A12 (3) R ACCACCTAAGAACCCATCCA 
S100A12 (3) Pr TGCCCTTCACCACTGCTGGC 
P4 S100A12 (4) F GGGATGCAGGAGAACAGACA 
S100A12 (4) R GGCAGTTTGTGTTTGGTGGT 
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S100A12 (4) Pr TGCTCCCACTGCCTGGTGCT 
P5 S100A12 (5) F CAATCAAGGCCATGCCAGAA 
S100A12 (5) R CACATGGATCGGAGAGACAGA 
S100A12 (5) Pr TGTGCCCACCGACCTCTCTGG 
 
2.10 Statistical analysis 
Statistical analysis was done by use of GraphPad Prism. Normality was tested before every 
assay. Bar graphs show mean ± SD, box & whiskers with 5-95% Confidence Intervals or data 
is shown as percentages where appropriate. The significance of the data was analysed using 
Student's t-test for parametric data and the Mann–Whitney test for nonparametric data, unless 
stated differently. The Pearson product-moment correlation was performed to measure the 
linear correlation between two variables X and Y. Two-way ANOVA was used for more than 
two groups followed by multiple comparisons tests. P < 0.05 was considered statistically 
significant, ns = non significant, P > 0.05*, P ≤ 0.05**, P ≤ 0.01 and ***P ≤ 0.001. 
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3 RESULTS 
3.1 Regulation of S100A9 and S100A12 expression 
3.1.1 Hyperglycemia enhances the expression levels of S100A9, S100A12 among 
other genes in macrophages 
To confirm results of Affymetrix chip analysis mRNA expression of S100A9 and S100A12, 
were verified by RT-PCR and two other genes; CCL24 - Chemokine binding to CCR3, 
eosinophil chemoattractant (Menzies-Gow, Ying et al. 2002) and ARRDC4 - Adaptor protein 
with potential role in endocytosis of G protein-coupled receptors, which, when overexpressed, 
inhibits glucose uptake (Patwari, Chutkow et al. 2009).  
S100A9 and S100A12 were significantly higher expressed in M1 macrophages (P= 0.0155) 
and significantly lower expressed in M2 macrophages (P = 0.0194) under normal glucose 
conditions (Fig. 1). It was shown that hyperglycemia induces significantly higher levels of 
S100A9 in M0 macrophages, up to 2.5-fold for individual donors (P = 0.0257) but mostly 
increased in M1 macrophages, which are stimulated with IFNγ, up to 4.4 fold increase (P = 
0.0097) (Fig. 1). For S100A12 a similar effect was seen; after six days hyperglycemia induced 
significantly higher levels of S100A12 expression in M0 macrophages, up to 4.9 fold increase 
for individual donors (P = 0.0257) but mostly increased in M1 macrophages, up to 9.8 fold 
increase for individual donors (P = 0.0097) (Fig. 5).  
Hyperglycemia also had an inducing effect on both ARRDC4 and CCL24 in different 
macrophage subtypes. Under normal glucose conditions ARRDC4 was highest expressed in 
M2 compared to M0 macrophages (P = 0.0027). Glucose up regulated ARRDC4 gene 
expression in all donors and in both M1 and M2 macrophages. We found the strongest 
increases for individual donors in M1 conditions; up to 12.9-fold increase. CCL24 was not 
differentially expressed in M1 and M2 polarized macrophages under normal glucose 
conditions compared to M0 macrophages. Glucose increased the expression of CCL24 in 7 
out of 9 donors for M0 and 5 out of 9 donors for both M1 and M2 polarized macrophages. We 
find the highest CCL24 expression and also the highest increase induced by glucose in 
individual donors in M1 polarized macrophages (Fig. 5). 
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Figure 5. Analysis of the effect of hyperglycemia on the expression of ARRDC4, CCL24, S100A9 
and S100A12. mRNA expression was analysed by RT-PCR in M0, M1 and M2 macrophages cultured 
for 6 days under normal (NG, 5mM) and high glucose (HG, 25mM) conditions. Data present mean ± 
SEM normalized to 18SrRNA expression levels. N=9 for ARRDC4 and CCL24, n=6 for S100 genes. 
*p<0,05.  
 
3.1.2 Cultivation in high glucose conditions does not change glucose uptake of M0 
and M1 macrophages 
The first step in glucose response is the entry of glucose into the cell. Since glucose 
metabolism determines immune cell activation and also long-term training of monocytes via 
the AKT–mTOR–HIF-1a pathway (Cheng, Quintin et al. 2014). Van Diepen et al. 
hypothesized that high circulating levels of glucose could program immune cells towards an 
inflammatory phenotype (van Diepen, Thiem et al. 2016). GLUT1 is the primary rate-limiting 
glucose transporter for proinflammatory macrophages (Freemerman, Johnson et al. 2014). 
2-deoxc-2-[(7-nitro-2,1,3-benzoxadiazol-4-y)amino]-D-glucose or 2-NBDG was added to M0 
and M1 macrophages which were on zero glucose medium for 2 hours. Uptake of the 2-
NBDG was higher in M1 compared to M0 macrophages with 200 µg of 2-NBDG added. High 
glucose culture did not change the glucose uptake in M0 nor in M1 macrophages (Fig. 6).  
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Figure 6. Glucose uptake was not affected by hyperglycemic conditions. M0 and M1 macrophages 
were cultured for 6d. Medium was changed to zero glucose medium and glucose uptake was measured 
after two hours by addition of 2-NBDG (100 and 200µg/ml) and control inhibitor of glucose uptake 
WZB (100µM). Statistical analysis was performed using paired two-tailed t-test. The difference was 
considered to be statistically significant in case of *p<0.05, n=4.  
 
3.1.3 Hyperglycemia supports the expression of S100 genes during 
monocyte/macrophage differentiation under IFNγ stimulation 
We determined the expression of S100A9 and S100A12 at different stages of maturation from 
monocytes into macrophage. It is known that S100A8 and S100A9 mRNA levels decline 
during monocyte differentiation into macrophage (Averill, Barnhart et al. 2011). In our 
experiments, the expression of S100 mRNA drops during differentiation in all conditions (ns, 
IFNγ, IL-4). After S100A9 is highest expressed in M1 macrophages compared to S100A12 in 
M0 macrophages. Both genes were higher expressed in monocytes than macrophages and 
S100A12 was downregulated stronger during maturation into macrophages than S100A9 (Fig. 
7). But on the late stages of differentiation IFNγ again induces S100A9 and S100A12. In 
addition, in high glucose conditions 9 out of 10 donors showed increased S100A9 expression 
induced up to 4.9 fold (P= 0.0019) after 6 days, whereas 8 out of 10 donors showed increased 
S100A12 expression induced by glucose up to 3-fold (P= 0.0155) after 6 days. 
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Figure 7. The expression levels of S100A9 and S100A12 are elevated by hyperglycemia in 
macrophages after 6 days. RT-PCR analysis of mRNA expression S100A9 and S100A12 in M0, M1 
and M2 macrophages cultured under normal (NG) and high glucose (HG) conditions. Data present 
mean ± SD normalized to 18SrRNA expression levels. n = 9 and 8 respectively *p<0.05, **p<0.01 
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3.1.4 Hyperglycemia affects S100A9/A12 gene expression ratios 
Since S100A9 is able to form heterodimers with S100A8 upon activation  (Vogl, Gharibyan et 
al. 2012), we measured mRNA levels of S100A8 in monocytes and macrophages from healthy 
donors. In contrast to S100A9 and S100A12 which are abundantly present in monocytes 
compared to matured macrophages we find that S100A8 is present at mediate levels in 
monocytes compared to the maturated macrophages (data not shown). Under NG conditions 
the expression levels of S100A8 and S100A9 always significantly correlated whereas highest 
correlation was seen in M2 macrophages. Under HG conditions this correlation was even 
stronger, specifically in M0 and M2 macrophages (Table 16).  
As analysis of calgranulin gene expression revealed higher levels of both S100A9 and 
S100A12 in macrophages cultured under high glucose conditions, it was examined whether 
there is a correlation between S100A9 and S100A12 expression levels in the different subtypes 
of macrophages. Under NG conditions the expression levels of S100A9 and S100A12 
significantly correlated in M0 and M1 but not M2 macrophages. Under HG conditions this 
correlation between S100A9 and S100A12 expression decreased in favour of S100A9 (Table 
16). In summary, S100A8 alone or as heterodimer with S100A9 seemed to be relevant in M2 
macrophages as there almost linear correlation is found between S100A8 and –A9 expression 
levels. S100A9 and S100A12 expression are correlated in M0 and M1 macrophages, however 
under high glucose conditions this correlation decreased. The regulation of expression and 
ratio of the different S100 genes might provide more insight in the mechanism of 
inflammation. 
 
Table 16. Linear regression analysis of S100 gene expression in human primary 
macrophages. 
Gene NG HG 
S100A8 / S100A9 M0 R
2 
0,7603 0,8465 
  
p value 0,0235* 0,0093** 
 
M1 R
2 
0,8275 0,833 
  
p value 0,0119* 0,0111* 
 
M2 R
2 
0,7695 0,8924 
  
p value 0,0217* 0,0045** 
S100A9 / S100A12 M0 R
2 
0,519 0,05307 
  
p value 0,0286* 0,5831 
 
M1 R
2 
0,9251 0,6 
  
p value < 0,0001*** 0,0085** 
 
M2 R
2 
0,2859 0,405 
  
p value 0,138 0,0654 
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3.1.5 S100 Protein expression 
We measured protein levels of S100A9 and S100A12 in monocytes and macrophages from 
healthy donors by Western blot. Similar as observed for mRNA expression, we find on 
protein level that S100A9 and S100A12 protein are more abundantly present in monocytes 
compared to matured macrophages (not shown). S100A9 is expressed in all types of 
macrophages. Both proteins were typically expressed in M1 macrophages (Fig. 8). During 
stimulation of cells with IL-4 S100A12 was deficient in some donors in M2 macrophage 
population, similar as seen on 
mRNA level before. Further 
differences in expression relate 
to different donor responses 
(Fig. 8). Thus, macrophages 
contain high levels of 
intracellular S100 proteins and 
protein expression had not 
changed significantly by 
stimulation with cytokines or 
culture under high glucose. 
 
Figure 8.  S100A9 and S100A12 
protein expression in primary 
human macrophages. Western 
Blot analysis of protein 
expression S100A8, -A9  and 
S100A12 (n=6) in M0, M1 and 
M2 macrophages cultured for 6 
days cultured under normal (NG) 
and high glucose (HG) 
conditions.  
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3.1.6 Secretion of S100A9 and S100A12  
S100 proteins are either expressed intracellular or secreted into the extracellular space 
(Donato, Cannon et al. 2013). Secreted forms of S100A9 and S100A12 proteins were 
assessed by ELISA in different types of macrophages cultured in NG and HG conditions (Fig. 
9). Secretion of S100A9 and S100A12 was measured at different time points; 6h, 24h and 6d 
after seeding the monocytes.  
For S100A9 secretion, no significant effects were observed after 6 and 24 hours. After 6 days, 
there was a slight increase of secretion levels in M2 macrophages cultured in high glucose 
conditions compared to normal glucose (P = 0.0361 by student’s t-test). The highest levels of 
S100A9 secretion we find in M1 macrophages with ranges between 990.7 ± 264.5 pg/ml 
under normal glucose conditions. HG medium tend increase to secretion of S100A9 in all 
types of macrophages but not to a significant level.  
After 6 days, S100A12 secretion was lower in M2 macrophages compared to M0 
macrophages under normal glucose conditions (P=0.0248). The highest levels of S100A12 
secretion we find in M0 macrophages with ranges between 32997 ± 26615 pg/ml under 
normal glucose conditions. HG medium decreased secretion levels in M0 macrophages 
(P=0.0006). This effect was already seen after 24 hours already (P = 0.0328) (Fig. 9). 
The data on secretion are much lower than serum levels seen in diabetic patients, seen from 
literature (Bouma, Lam-Tse et al. 2004, Nagareddy, Murphy et al. 2013, Ingels, Derese et al. 
2015). It seems that macrophages cannot release the intracellular accumulated S100 protein, 
release only standard amount in cell culture or need an addition trigger from the in vivo 
microenvironment to be able to secrete the S100 protein e.g., cytokines, Fatty Acids (FA), 
AGEs or direct contact with activated endothelium or tend to have more intracellular 
functions.  
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Figure 9. The effect of hyperglycemia on secretion of S100A9 (A) and S100A12 (B) in cultured 
M0, M1 and M2 macrophages after 6h, 24h and 6d (n=6). Data after 6d expressed as fold change 
increase compared to ns NG control (C). Student t-test and Two-way ANOVA for groups were used, 
n=6. 
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3.2 Expression of S100 proteins in diabetic patients 
3.2.1 Gene expression in PBMCs of diabetic patients 
Next we identified whether S100 genes are higher expressed and therefore relevant in 
prediabetic and diabetic patients. PBMCs of diabetic patients were kindly provided by Dr. 
Thomas Fleming (Department of Medicine I and Clinical Chemistry, Heidelberg-clinic). We 
measured gene expression of the individual genes in fractioned PBMC fractions and 
normalized to the expression of monocyte marker CD14. Within the group of T1D patients 
75% of the subjects suffered from neuropathy, 37.5% retinopathy and 17.6% nephropathy in 
T1D. Also, patients with T2D diabetes suffered from polyneuropathy (76.2%) and 
nephropathy (52.4%) and showed albuminuria (Table 17). 
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Figure 10. Fasting glucose and HbA1c levels in prediabetic individuals, diabetic patients and 
healthy controls. Pre-diabetic subjects were defined based on increased fasting glucose between 100-
125mg/dl or an impaired glucose tolerance – with elevated blood glucose levels between 140-
199mg/dl after intake of 75g glucose. Control (n=21), Prediabetic (n=19), T1D (n=19) and T2D 
(n=21). 
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Table 17. Characteristics according to patient diagnosis. 
 T1D (n=19) T2D (n=21) Prediabetic 
(n=19) 
Control 
(n=21) 
Age (years) 50,2 ± 18,1 59,7 ± 6,1 59,1 ± 7,6 57,9 ± 7,4 
Sex (women) 56% 48% 47,4% 57% 
Diabetes duration 
(years) 
31,1 ± 14,4 9,7 ± 6,0   
Size (cm) 172 ± 11 171 ± 10 171 ± 8 169 ± 10 
Weight (kg) 79,8 ± 15,6 96,8 ± 19,6 * 97,8 ± 21,7 * 84,0 ± 18,2 
BMI (kg/m2) 26,8 ± 4,3 31,4 ± 9,3 33,4 ± 7 * 29,2 ± 4,3 
Smoking (%)  20,0 25,0 5,6 - 
Retinopathy (%) 37,5 * 14,3 5,3 4,8 
Polyneuropathy (%) 75,0 *** 76,2 *** - - 
Fasting glucose 
(mg/dl) 
177,2 ± 63,4 *** 167,0 ± 52,2 *** 106,7 ± 7,5 *** 90,2 ± 9,4 
HbA1c 8,3 ± 1,6 *** 7,5 ± 1,2 *** 5,6 ± 0,4 5,5 ± 0,3 
eGFR  
 
95,6 ± 13,3 87,8 ± 11,9 92,9 ± 14,5 
Urine Creatinine 91,9 ± 56,8 108,4 ± 63,3 130,5 ± 79,6 113,8 ± 
57,2 
Urine Albumin 39,9 ± 67,5 88,8 ± 137,8 * 13,9 ± 11,1 8,3 ± 4,0 
U_ACR 16,0 ± 18,4 22,0 ± 27,4 2,9  
Nephropathy (%) 17,6 * 52,4 *** 11 - 
NSS 4,0 ± 2,6 6,2 ± 2,5   
NDS 4,1 ± 3,0 4,5 ± 2,8   
 
Values represent mean ± SD or percentages (%). Control vs. other groups *p < 0.05, **p < 0.01 *** p 
< 0.001. BMI – Body Mass Index, eGFR - Estimated Glomerular Filtration Rate, ACR - 
albumin/creatinine ratio, NSS - Neuropathy Symptoms Score, NDS - Neuropathy Disability Score. 
 
We measured gene expression levels in PBMCs and normalized to CD14. Data were not 
normally distributed therefore we presented the medians. We found S100A9 tend to be higher 
expressed in T2D whereas S100A12 was higher expressed in T1D patients (not significant by 
Kruskal-Wallis test) (Fig. 11). However, we found similarly that S100A9 and S100A12 
expression are very tightly correlated in T1D, T2D and healthy controls (P = < 0.0001 for all 
three) but not in prediabetic individuals (Table 18). 
Then, it was examined whether correlations found for are specific for S100 genes other 
inflammatory macrophage markers IL-1B and CCR2. We found IL1B tend to be higher 
expressed in T2D (not significant by Kruskal-Wallis test). The CCR2 expression did not differ 
between the groups.  
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Table 18. Correlation between S100A9 and S100A12 expression in monocytes from healthy 
controls, prediabetic individuals and diabetic patients, normalized to CD14 expression. 
Patient PBMCs normalized to CD14+ 
 
Control Prediabetic T1D T2D 
R
2 
0,8091 0,1403 0,878 0,9778 
p value < 0,0001*** 0,169 < 0,0001*** < 0,0001*** 
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Figure 11. RT-PCR analysis of IL-1B, CCR2, S100A9 and S100A12 expression in PBMCs from 
prediabetic individuals, diabetic patients and healthy controls normalized to CD14 expression. Data 
present medians. Kruskal Wallis followed by Dunn's multiple comparisons test. 
 
Regarding the variables age, weight, BMI, glucose and HbA1c the ANOVAs yielded 
significant results (Scheffe’s post hoc test used for pairwise comparisons). According to 
descriptive statistics for the total group (n = 76), the distributions of the gene expressions are 
skewed and not normally distributed. Therefore, logarithmic transformation was used for 
statistic tests. Pearson correlation coefficients showed no significant correlation between 
inflammatory gene expression and fasting glucose levels in prediabetic individuals. Yet, 
diversity in expression resembles diversity in response but not the absence of response. Some 
individuals with high expression show high FG levels (Fig. 12). We did not observe a 
correlation between gene expression levels and HbA1c levels, BMI or weight as well (data 
not shown). 
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Figure 12. Correlation between IL-1B and CCR2, S100A9 and S100A12 expression and fasting 
glucose in pre-diabetic individuals. Number of XY Pairs = 16. Graphs show 95% confidence band of 
best-fit line. Correlation coefficient (r) and p-value are given in the graphs. 
 
3.2.2 Protein expression in monocytes of diabetic patients 
Since no significant changes in S100A9 and –A12 gene expression levels were found in 
diabetic patients we sought to investigate protein levels in PBMCs of patients with 
microvascular complications. Plasma levels of S100 proteins have been assessed in diabetic 
patients but not protein expression in blood cells (Basta, Sironi et al. 2006, Pedersen, Nybo et 
al. 2014, Dong, Shi et al. 2015). To this end, intracellular expression levels of S100A9, 
S100A12 were assessed in monocytes form T2D with cardiovascular disease 
and/nephropathy. First, changes in different monocyte subsets were characterised; designated 
as classical (CD14+ CD16-), intermediate (CD14+ CD16+) and non-classical monocytes with 
low CD14 expression (CD14- CD16+).  
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Table 19. Clinical characteristics of the patients and control individuals. 
Variable Healthy controls (n=5) T2D with complications (n=12) 
Age (years) 54,0 ± 12,1 67,4 ± 10,8 
Sex (%female) 100% 42% 
BMI (kg/m2) 25,1 ± 2,4 31,5 ± 6,1 
Waist circumference (cm) 85,4 ± 3,4 111,6 ± 14,2 
Current smoke (%) 20% 16% 
Hypertension 0% 83% 
Cardiovascular disease (%) 0% 67% 
Cholesterol (mg/dl) (mmol/l) 200,0 ± 46,0 196,2 ± 60,2 
HDL (mg/dl) (mmol/l) 71,2 ± 29,6 44,5 ± 10,3 
LDL (mg/dl) (mmol/l) 114,8 ± 26,4 107,8 ± 49,4 
Triglycerides (mg/dl) (mmol/l) 70,6 ± 39,0 304,2 ±389,1 
Glucose (mg/dl) (mmol/l) 89,8 ± 7,4 192,9 ± 101,4 
HbA1c (%) (mmol/l) 5,4 ± 0,1 7,9 ± 1,4 
 
Values represent mean ± SD or percentages (%). Control vs. other groups *p < 0.05, **p < 0.01 *** p 
< 0.001. BMI – Body Mass Index, HDL - High-density-lipoprotein, LDL – Low-density-lipoprotein, 
HbA1c - Hemoglobine A1c 
 
First, we evaluated whether the distribution of the different monocyte populations had 
changed in T2D compared to healthy controls. We found that the most abundant were 
classical monocyte population, which encompassed 10.5 ± 7.8% of the total monocyte 
population for healthy individuals compared to 12.4 ± 7.8% of T2D patients with cell counts 
between 2252 and 41899 (Fig. 13A).  
In the diabetic subgroups healthy control group showed the least and T2D with cardiovascular 
complications (CVD) the relative highest number of classical CD14+ monocytes, whereas 
T2D+CVD with additional nephropathy (N) showed the highest number of intermediate 
monocytes CD14+, CD16+ (Fig. 13B). 
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Figure 13. Classical, intermediate and non-classical monocytes subsets from T2D patients with 
microvascular complications were analysed based on CD14+ and CD16+ expression by FACs. Cells 
positive for HLA-DR were selected and all cells expressing CD3, CD19 and CD56 were excluded. A) 
Monocyte subsets in total T2D group compared to healthy controls. B) Monocyte subsets in T2D 
patients with different vascular complications compared to healthy controls. Cardiovascular disease 
(CVD), nephropathy (N) and both, compared to healthy controls. Mann Whitney test (A) and One-way 
ANOVA with Dunnett's multiple comparisons test (B) were used. 
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Next, expression of S100A9 was analysed in the different monocyte populations as its 
expression has been shown to vary between the monocyte populations of healthy donors 
(Yang, Anholts et al. 2018). The median fluorescence intensity (MFI) of S100A9 in classical 
monocytes was 1.18 times (12703 MFI units), higher compared to 4.08-fold (5193 MFI units) 
in non-classical monocytes and 1.39 times (35085 MFI units) fold in intermediate monocytes 
(Fig 14). Thus, for T2D patients with microvascular complications highest absolute increase 
in S100A9 expression was observed in the intermediate monocytes.  
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Figure 14. Intracellular S100A9 expression in different monocyte populations. Protein expression 
was analysed by FACS in cells positive for HLA-DR negative for CD3, CD19, CD56 were excluded. 
T2D patients with microvascular complications, cardiovascular disease (CVD), nephropathy (N) and 
both (n=21) compared to healthy controls (n=5).  
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Figure 15. Intracellular expression levels of S100A9, S100A12 in CD14+ monocytes from T2D 
patients with microvascular complications and healthy controls. Protein expression was analysed 
by FACS in cells positive for HLA-DR negative for CD3, CD19, CD56 were excluded. T2D patients 
with microvascular complications, cardiovascular disease (CVD), nephropathy (N) and both (n=21), 
compared to healthy controls (n=5).  
 
When evaluating S100A9 and S100A12 expression in all CD14+ positive cells and within the 
different T2D subgroups according microvascular complications, protein expression of 
S100A12 has increased significantly in T2D compared to controls (P<0.05). When evaluating 
the different subgroups with complications, it was observed that S100A9 and S100A12 levels 
were increased in T2D + CVD patients whereas this was statistically significant for S100A12 
(Fig. 15). 
No correlations of S100A9, S100A12 protein expression were found with HbA1c. Also, there 
were no correlation of frequency of the different monocyte populations with HbA1c levels 
(Fig. 16). Further no correlations were found between S100A9, S100A12 protein expression 
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and other metabolic factors (BMI, HDL or fasting glucose). Only, S100A9 expression in non-
classical CD14-CD16+ cells were correlated with BMI, P = 0.0345 (data not shown).   
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Figure 16. Correlation of protein expression levels of S100A9, S100A12 (A) and monocyte 
populations (B) with HbA1c level in T2D patients with microvascular complications (n=15). 
Correlation was analysed using Pearson’s r coefficient, showing 95% confidence band of the best-fit 
line.  
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3.3 Chromatin Immunoprecipitation (ChIP)  
3.3.1 Design of ChIP primers and optimization of ChIP 
We examined the promoters of S100A9 and S100A12 genes for activating and repressive 
histone marks in order to design primers for ChIP analysis by RT-PCR. The UCSC genome 
browser provides the histone modifications for cell lines included in the Encyclopedia of 
DNA Coding Elements (ENCODE) and was used for experimental design in order to define 
the histone marks to be analysed by ChIP. The use of specific primers for each histone mark 
within a promoter increases the sensitivity of the assays. Within the UCSC Genome Browser 
on Human Feb. 2009 (GRCh37/hg19), we used the ENCODE Histone Modification Tracks 
which displays Histone Modifications by ChIP-seq from ENCODE/Broad Institute and from 
the subtracks by antibody and cell line we selected Monocytes CD14+ RO01746 (Tier 2). In 
UCSC we selected S100A9, S100A12 genes and used up to 3000bp upstream of the TSS to 
scan for suitable ChIP primers (Fig. 17). 
 
Figure 17. Different promoter regions for which qRT-PCR primers were designed. Regions were 
chosen based on UCSC genome browser available Chipseq data for monocytes for the histone 
modifications H3K4me1, H3K4me3 S100A9 promoter (left), S100A12 promoter (right). 
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3.3.2 Optimization of ChIP 
ChIP is a valuable tool to compare transcription factors or modifications of DNA-bound 
proteins to specific genes across the genome. Macrophages were formaldehyde-crosslinked, 
and chromatin was prepared and digested by Micrococcal Nuclease. Optimal duration and 
concentration of micrococcal nuclease were determined for digestion. The digestion by 
enzyme has been very stable between the different experiments and we obtained fragment 
sizes between 150 and 1000bp (Fig. 18).  
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Figure 18. Agarose gel for varying digestion by Micrococcal Nuclease.  For ChIP approximately 5 
X 10
6
 cells for each IP prep were considered optimal. For determination of the optimal digestion 
conditions different time (A) and different volume of Micrococcal Nuclease (B) were added per 100 µl 
nuclei preparation.  
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3.3.3 Hyperglycemia contributes to association of activating histone marks at S100A9 
and A12 promoters 
Using four individual donors, we have analyzed the abundance of epigenetic marks in five 
regions of S100 gene promoters. Hyperglycemia enhanced increase of activating histone 
modifications H3K4me1, H3K4me3 and AceH3 was similar at promoters of S100A9 and 
S100A12 in M1 macrophages. Only the level of AceH3 had significantly changed at both 
S100A9 and S100A12 promoters (P = 0.0024 and 0.0004 respectively) (Fig. 19). Thus, histone 
code at S100 promoters had changed by culture under HG conditions.  
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Figure 19. Hyperglycemia enhances activating histone code at promoters of S100A9 and 
S100A12 in M1 macrophages. Level of histone modifications in S100A9 (top) and S100A12 
(bottom) promoter regions, average of 5 regions in the promoter, Min to Max plot. Rabbit IgG 
was used as a negative control for the pull-down. Histone modifications are presented as 
percent of input DNA and normalized to total H3 (by D2B12 antibody) (n=4).  
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3.3.4 ChIP analysis of histone code on 5 different regions of S100A9 and S100A12 
promoters 
Next, we analysed five regions at different distances from the TSS of the promoter to 
investigate the regions with the most pronounced presence of each activating histone mark 
and the regions which are most affected by glucose (Fig.20). By two-way ANOVA was 
determined how two factors i.e. promoter region and glucose influence the abundance of the 
antibody binding. Association (regardless of glucose) was not the same in the different 
regions of the S100A9 promoter (H3K4me3, P < 0.0001 and AceH3, P = 0.0137). The site 
with highest association of histone modification with the S100A9 promoter H3K4me3 was at 
the TSS whereas general acetylation has highest binding affinity at 1200 and 1600bp 
upstream from the TSS. Also promoter regions were identified which were mostly affected by 
culturing cells under high glucose conditions. General acetylation on the promoter of S100A9 
was significantly affected (AceH3, P = 0.0157). For the S100A12 promoter the abundance of 
histone marks did not significantly differ depending on glucose or promoter region. 
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Figure 20.  Histone code at 5 single regions in promoters in M1 macrophages. Level of activating 
histone marks at each single promoter region (P1-P5) of S100A9 (top) and S100A12 (bottom). Rabbit 
IgG was used as a negative control for the pull-down. Histone modifications are presented as percent 
of input DNA and normalized to total H3 (by D2B12 antibody). Graphs represent mean + SEM (n=4).  
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3.3.5 Correlation gene expression of S100A9 and S100A12 and histone modifications 
to their respective promoters 
Next, we investigated the correlation of S100A9 and S100A12 glucose-induced changes in 
gene expression and glucose-induced changes in the presence of the activating histone marks 
on their respective promoters. Gene expression was increased under hyperglycemic conditions 
in M1 macrophages in 3 out of 4 donors for both S100A9 and S100A12 (Fig. 21). Association 
of level of changes in the association of activating histone marks correlated negatively with 
the level of the increase in the gene expression. Donors 1 and 2 which show highest level of 
gene expression and increase upon culture in HG conditions did not show pronounced 
epigenetic changes (Fig. 21) whereas donor 3 and 4 respond with increased levels of 
H3K4me1, H3K4me3 and AceH3. Therefore, fold change increase in gene expression 
correlated negatively with increase in level of histone mark. On the other side, we observed 
that total H3, representing the nucleosome density, was reduced under HG conditions in all 
donors (Fig. 21; Fig. 22). 
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Figure 21. Increase in gene expression is not associated with increased level of activating 
histone marks in M1 macrophages. mRNA levels of S100A9 and S100A12 in M1 
macrophages cultured for 6 under NG or HG conditions (n=4) (top). Heatmap of histone 
modifications at S100A9 and S100A12 promoter of the 4 individual donors (bottom).  
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Figure 22.  Increase in gene expression correlates with change in total H3 in M1 
macrophages. Total endogenous H3 levels on the promoter regions of S100A9 and S100A12 
average of 5 regions in the promoter (n=4) (top). Linear regression of fold change increase in 
gene expression (x-axis) with fold change increase of total H3 (y-axis) due to culture under 
HG conditions (bottom). Stdev presents average of 5 primer regions. 
 
Stronger induction of gene expression by HG then was associated with higher density of 
nucleosomes i.e. positive correlation of fold change in total H3 with fold change in gene 
expression for the individual donors (Fig. 22).  
Next, the changes in levels of H3 in specific promoter regions were examined. For S100A9 P2 
and P4 region as well as P1 region within S100A12 promoter, which is the nearest region to 
the transcription start site, an almost linear correlation was observed between fold change 
increases in H3 and fold change increase in gene expression (Fig. 23). In summary, high 
glucose culture enhanced the presence of activation histone marks on average and decreased 
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the level of total H3. The change in levels of total endogenous H3 is positively correlated to 
fold change increases in gene expression.  
 
0 1 2 3 4
0 .5
0 .6
0 .7
0 .8
0 .9
1 .0
P 1
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
0 1 2 3 4
0 .4
0 .6
0 .8
1 .0
1 .2
P 2
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
0 1 2 3 4
0 .0
0 .5
1 .0
1 .5
P 3
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
0 1 2 3 4
0 .0
0 .5
1 .0
1 .5
P 4
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
0 1 2 3 4
0 .0
0 .5
1 .0
1 .5
P 5
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
0 1 2 3 4 5
0 .0
0 .5
1 .0
1 .5
P 1
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
0 1 2 3 4 5
0 .5
0 .6
0 .7
0 .8
0 .9
P 2
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
0 1 2 3 4 5
0 .0
0 .5
1 .0
1 .5
P 3
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
0 1 2 3 4 5
0 .0
0 .5
1 .0
1 .5
P 4
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
0 1 2 3 4 5
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
P 5
F o ld  ch a n g e  m R N A
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
S 1 0 0 A 9
S 1 0 0 A 1 2
*
* *
*
 
Figure 23. Relation H3 occupancy and gene expression depends on promoter region in 
M1 macrophages. Linear regression of the histone mark association with fold change 
increase in gene expression (x-axis) with fold change increase of total H3 (y-axis) by culture 
under HG conditions. Correlation was shown for 5 single regions in promoters (P1 – P5) of 
S100A9 (top) and S100A12 (bottom). The correlation was considered to be statistically 
significant in case of *p<0.05 by linear regression analysis. 
 
3.4 Histone modifying enzymes 
3.4.1 Inhibition of SET7 affects both S100A9 and S100A12 expression 
As hyperglycemia resulted in the enhanced association of activating histone marks H3K4me1, 
H3K4me3 on promoters of S100A9 and S100A12, our next aim was to identify which histone 
modifying enzymes is mediating methylation. Histone methyltransferases responsible for 
H3K4me are the MLL/KMT2 family, SET1A, SET1B, SET7/9, SMYD and PRDM9 where 
SET7 specifically exhibits monomethylation activity and MLL1/2 and MLL3/4 trimethylation 
of H3K4 (Khare, Habib et al. 2011). SMYD3 catalyses trimethylation of histone H3K4 and is 
mostly associated with cancer, but cancer cells share metabolic similarities with immune cells 
(Andrejeva and Rathmell 2017). SET7 has been shown to be sensor for hyperglycemic 
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changes in EC (El-Osta, Brasacchio et al. 2008) whereas MLL has been found to be important 
in macrophages differentiation (Kaikkonen, Spann et al. 2013, Kittan, Allen et al. 2013). We 
analyzed the regulatory effect of HMTs on transcription of S100A9 and –A12 using specific 
inhibitors; (R)-PFI-2 hydrochloride, a substrate-competitive inhibitor which occupies the 
substrate peptide binding groove of SETD7 (Barsyte-Lovejoy, Li et al. 2014), EPZ031686 
inhibitor for SMYD3 (Mitchell, Boriack-Sjodin et al. 2015) and WDR5 0103 inhibitor of 
MLL which disrupts WDR5 interaction with MLL and inhibits MLL core complex 
methyltransferase activity (Senisterra, Wu et al. 2013). The application of the inhibitors did 
not affect the viability of cells, tested by Alamar blue (Fig. 24). 
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Figure 24. Macrophage viability/metabolic activity after treatment with HMT inhibitors. 
Following inhibitors were used: PFI-2 hydrochloride, EPZ031686 and/or WDR5 0103. Corresponding 
concentrations of DMSO were used as vehicle controls. M1 macrophages were cultured for 6 days 
followed by measurement of metabolic activity using Alamar blue assay. Data present mean ± SD for 
6 donors. 
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Figure 25. Regulation of S100A9 and S100A12 gene expression by HMTs in M1 macrophages. 
RT-PCR analysis of the effect of treatment with PFI-2 hydrochloride inhibitor for SET7 in 5 and 
10μM concentrations corresponding to 1/2000 and 1/1000 dilutions of DMSO (A), EPZ031686 
inhibitor for SMYD3 in 10 and 20μM concentrations corresponding to 1/1000 and 1/500 dilutions of 
DMSO (B) or WDR5 0103 inhibition of MLL activity in 5, 25 and 100μM concentrations 
corresponding to negligible, 1/4000 and 1/1000 dilutions of DMSO (C). Data present mean ± SEM 
normalized to 18SrRNA levels, n=5 *p<0.05, **p<0.01. 
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In the experiment where PFI-2 inhibitor of SET7 was applied (Fig. 25A), high glucose 
increased the expression of S100A9 and –A12, but not so significant level, in the absence of 
inhibitors. It significantly up regulated expression in the macrophages treated with vehicle 
control for 5µM PFI-2 (P 0.0315 and 0.0290 for both genes respectively). In case of 
macrophages treated with inhibitor PFI-2 at both concentrations S100A9, and S100A12 gene 
expression was significantly down-regulated compared to its DMSO control in the cells 
cultured under high glucose conditions.  
In the experiment where EPZ03 inhibitor of SMYD3 was applied (Fig. 25B), high glucose 
highly increased the expression of S100A9 and –A12, but not to a significant level in the 
absence of inhibitors. Expression of both genes was significant up regulated expression in the 
vehicle controls (P 0.0238 for S100A9) or inhibitor (EPZ03 10µM, P= 0.0472 for S100A12). 
In case of macrophages treated with inhibitor EPZ03 S100A9 expression did not change. For 
S100A12 expression application of EPZ03 abolished the effect of high glucose. This effect of 
EPZ inhibition was seen in highest concentration and did not reach significance when 
compared to its vehicle control (P = 0.0529).  
In the experiment where WDR5 inhibitor of MLL activity was applied, high glucose highly 
increased the expression of S100A9 and –A12, but not to a significant level in macrophages in 
the absence of inhibitors as well as DMSO as a vehicle. Glucose up regulated S100 
expression in the macrophages treated with inhibitor (WDR5 25µM P= 0.0187 for S100A9). 
In case of macrophages treated with inhibitor, both S100A9 and –A12 expression did increase, 
which was significant for S100A9 (WDR5 25µM P= 0.0187). MLL inhibition seemed to work 
synergistically with glucose (Fig. 25C).  
Since the effect was observed both in normal and hyperglycemic conditions, we conclude that 
HMTs act on the mentioned promoters independent of the influence of glucose (NG vs HG).  
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3.4.2 Glucose affects SET7 gene expression in M1 macrophages 
Histone methyltransferases SET7 has emerged as a key regulatory enzyme in mediating 
methylation of lysine residues at histone tails and non-histone protein targets (Keating and El-
Osta 2013). Also, it has shown to play a role in sustained enrichment of H3K4me1 at the 
RELA promoter encoding NFκB subunit p65, in primary human and bovine endothelial cells  
indicating a role in metabolic memory of previous exposure to glucose (El-Osta, Brasacchio 
et al. 2008). Therefore, we analysed SET7 expression during macrophage polarisation and 
under hyperglycemic conditions. We observed that SET7 expression had not changed in 
response to glucose or cytokines after one day (Fig. 26). Though after 6 days, when 
monocytes are maturated into macrophages, we found that SET7 expression is significantly 
increased, in 4 out of 6 donors for M1 and all donors for M2, compared to M0 macrophages 
under normal glycemic conditions (M1 P = 0.0049 vs M2 P = 0.0118) as well as 
hyperglycemic conditions (M1 P=0.0124 vs M2 P=0.0162) (Fig. 26). This indicates that 
macrophages need SET7 for activation, as SET7 expression is increased by both pro-
inflammatory cytokine IFNγ as well as anti-inflammatory cytokine IL-4. Further we found 
that glucose modestly but significant affected SET7 expression in M1 macrophages only (P = 
0.0100), suggesting that this gene encoding the histone modifying enzyme, is under metabolic 
control or affected by glycolysis.  
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Figure 26. SET7 mRNA expression during differentiation of macrophages. RT-PCR 
analysis of mRNA expression SET7 in M0, M1 and M2 macrophages cultured for 6 days 
cultured under normal (NG, 5mM) and high glucose (HG, 25mM) conditions. Data present 
mean ± SD normalized to 18SrRNA levels. Statistical analysis was found by paired student’s 
t-test, n = 6, *p<0.05, **p<0.01.  
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3.4.3 Effect of hyperglycemia on the localisation of SET7 in macrophages 
Additionally, SET7 was demonstrated to translocate to the nucleus in endothelial cells in 
response to high glucose (Okabe, Orlowski et al. 2012). the localisation of SET7 was 
investigated. M0 and M1 macrophages cultured under normal and high glucose conditions of 
seven individual donors were stained and SET7 protein expression and localisation was 
analysed by use of confocal microscopy. The appearance of the cells strongly changed by 
addition of IFNγ, whereas the cells lose their bigger round shaped form, become strongly 
adherent and stretch out M0 and M1 macrophages all contained large amount of intracellular 
SET7, and it was localized in the cytoplasm and in the nucleus (Fig. 27). Further, it was 
observed that IFNγ strongly induces SET7 protein expression after 6d in M1 of all individual 
donors (Fig. 27). Immunofluorescence imaging of M1 macrophages under normal and high 
glucose conditions indicate that hyperglycemia enhances the levels of nuclear translocation of 
SET7 in M1 macrophages (Fig. 28).   
 
 
 
Figure 27. SET7 expression is induced by IFNγ. Immunofluorescence/confocal imaging of 
SET7 protein expression in M0ns and M1IFNγ macrophages cultured for 6 days cultured under 
normal (NG, 5mM). Cells were stained with primary antibody against SET7 from Rabbit and 
secondary antibodies were Cy3 donkey anti-rabbit (red). Nuclei were visualised with and 
DRAQ5 (blue). Purple indicates localisation of SET7 in the nucleus (merging blue and red). 
Scale bars from top to bottom equal 50, 10 and 10μm.  
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Figure 28. Effect of hyperglycemia on the localisation of SET7 in macrophages. 
Immunofluorescence/confocal imaging of SET7 protein expression in M1 macrophages 
cultured for 6 days cultured under normal (NG, 5mM) and high glucose (HG, 25mM) 
conditions. Cells were stained with primary antibody against SET7 from Rabbit and 
secondary antibodies were Cy3 donkey anti-rabbit (red). Nuclei were visualised with and 
DRAQ5 (blue).. Purple indicates localisation of SET7 in the nucleus (merging blue and red). 
Scale bars from top to bottom equal 50, 10 and 10μm.  
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3.5 Metabolic memory 
3.5.1 S100 gene expression is sustained in transient hyperglycemia  
Transient hyperglycemia has been studied in vascular system and in the kidney i.e. endothelial 
cells (Chen, Wu et al. 2018) and mesengial cells (Yunlei, Qiuling et al. 2018) but not in cells 
of the innate immune system. We designed a model system for the analysis of hyperglycemic 
memory in primary human macrophages. After 6 days when the monocytes are differentiated 
into macrophages, the medium was changed, from containing NG to NG, from containing HG 
to HG and from containing HG back to NG (transient hyperglycemia). Macrophages from 7 
donors were analysed. Higher expression of S100A9 in HG-HG compared to NG-NG was 
observed (P = 0.0386) (Fig. 29). The increase was found in 5 out of 7 analysed donors with 
highest increase for individual donors being 2.8 fold. When the medium was changed back to 
normal glucose levels higher levels of gene expression compared to cells that were in NG 
medium continuously were found for 4 out of 7 donors.  
For S100A12, higher expression was observed in HG-HG compared to NG-NG conditions (P 
= 0.0056) (Fig. 29). Increased expression levels were found in 5 out of 7 analysed donors with 
highest levels for individual donors being 8.6 fold. When the medium was changed back to 
normal glucose higher levels of gene expression compared to cells that were in NG medium 
continuously (P = 0.0180). The increase was found in 6 out of 7 donors with highest levels of 
for individual donors being 5.7-fold (Fig. 29).  
Five out of 7 donors have higher expression of IL-1B in HG-HG medium compared to NG-
NG medium, though when the medium was changed back to normal glucose sustained levels 
of higher gene expression was found only for one donor. All donors had near significant 
higher expression of CCR2 in HG-HG compared to NG-NG (P= 0.0775), though higher gene 
expression levels were found for 4 out of 7 donors CCR2 expression was reduced back to 
normal in transient hyperglycemia.  
Thus, hyperglycemia causes memorable changes of S100 genes expression that last after the 
glucose concentrations are normalized. 
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Figure 29. Hyperglycemic memory in macrophages after 12 days. RT-PCR analysis of mRNA 
expression, from left to right; IL-1β and CCR2 (A) and S100 genes -A9 and S100A12in M1 
macrophages, individual patterns (left) and combined in box plots (right). After 6 days medium was 
changed and the cells were harvested at d12 for analysis. Data present mean ± SD normalized to 
18SrRNA levels. Statistical analysis was found by student’s t-test. The difference was considered to be 
statistically significant in case of *p<0.05. 
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3.5.2 Transient hyperglycemia results in decrease of activating histone marks at 
promoters of S100A9 and S10012 genes 
Next, using four individual donors, we performed ChIP analysis in our memory model with 
transient hyperglycemia. H3K4me3 as well as AceH3 on the promoter of both S100A9 and 
S100A12 were significantly decreased in cell cultured continuously under HG conditions. 
This decrease in AceH3 was reversible and not present any more in transient hyperglycemic 
cells (Fig. 30). H3K4me1 for S100A9 and H3K4me3 for S100A12 were sustained in transient 
hyperglycemia thereby possibly marking memory. Association of activating histone marks 
again negatively correlated with the increase in gene expression (data not shown). On the 
other side, we observed again that total H3 was reduced under HG conditions and this was 
reversible and not present in transient hyperglycemic cells (Fig.30).  
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Figure 30. Hyperglycemia decreases activating histone code at promoters of S100A9 and –A12 
after transient hyperglycemia. Level of histone modifications and total H3 in S100A9 and –A12 
promoter regions, average of 5 regions, Min to Max plot. Rabbit IgG was used as a negative control 
for the pull-down. Histone modifications are presented as percent of input DNA and normalized to 
total H3 (by D2B12 antibody) (n=4).  
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3.5.3 Correlation gene expression and histone code in memory model 
Gene expression was increased in M1 macrophages in 3 out of 4 donors for S100A9 and all 
donors for S100A12 in both HG as well as transient glucose vs NG, transient glucose still 
presenting 26 and 60% of the fold change increase induced by HG for S100A9 and –A12 
respectively (data not shown).  By two-way ANOVA it was determined how two factors i.e. 
promoter region and glucose influence the association of the histone mark at the promoter. 
For S100A9, the abundance of epigenetic marks, regardless of glucose, was not the same in 
the different promoter regions (H3K4me1 P = 0.0082, H3K4me3 and AceH3, P < 0.0001). 
The same held true for the S100A12 promoter (H3K4me3, P < 0.0001 and AceH3, P = 
0.0017). Only H3K4me3 association at the S100A12 promoter was significantly affected by 
glucose, regardless of the promoter region (P = 0.0335). Changes in H3 correlated positively 
with fold change increases in gene expression for S100A9 in transient hyperglycemia only 
(Fig. 31). To summarize, presence of activating histone marks on the promoters of S100A9 
and S100A12 had decreased after 12 days of culture with transient hyperglycemia. AceH3 and 
total H3 loss was reversible. H3k4me1 for S100A9 and H3K4me3 for S100A12 possibly mark 
metabolic memory.  
0 1 2 3
0.0
0.5
1.0
1.5
2.0
HG
Fold change mRNA
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
S
1
0
0
A
9
R
2
0,08877
ns
0 1 2
0.0
0.5
1.0
1.5
2.0
2.5
transient HG
Fold change mRNA
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
S
1
0
0
A
9
R
2
 0,8288
p < 0,0001
0 2 4 6 8 10
0.0
0.5
1.0
1.5
2.0
HG
Fold change mRNA
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
S
1
0
0
A
1
2
R
2
0,04377
ns
0 2 4 6
0.0
0.5
1.0
1.5
2.0
transient HG
Fold change mRNA
F
o
ld
 c
h
a
n
g
e
 T
o
ta
l 
H
3
S
1
0
0
A
1
2
R
2
 0,4915
p 0,0006
Total H3
%
 o
f 
in
p
u
t 
ra
ti
o
 t
o
 H
3
 (
S
1
0
0
A
9
)
N
G
-N
G
H
G
-H
G
H
G
-N
G
0
5
10
15
20
NG-NG
HG-HG
HG-NG
Total H3
%
 o
f 
in
p
u
t 
ra
ti
o
 t
o
 H
3
 (
S
1
0
0
A
1
2
)
N
G
-N
G
H
G
-H
G
H
G
-N
G
0
5
10
15
20
NG-NG
HG-HG
HG-NG
A
B
 
Figure 31. Modifications of histones at promoter regions in transient hyperglycemia. Level of 
total H3 in S100A9 (A) and –A12 (B) promoter regions, average of 5 regions, Min to Max plot and 
correlation of fold change increase in gene expression with increase of total H3 (n=4). 
RESULTS 
77 
 
3.6 Hyperglycemia sensitizes macrophages to exogenous and endogenous factors 
inducing S100A9 and S100A12 gene expression 
To investigate the effect of glucose on the training of macrophages, non-stimulated 
monocytes cells were cultured under NG and HG conditions and after 6 days they were 
challenged overnight with TLR-ligands. TLR receptors are known to be up regulated by 
glucose (unpublished observations of Michael Balduff) and act as receptors to mediate pro-
inflammatory involved in M1 macrophage activation during insulin resistance (IR)/metabolic 
disease (Olefsky and Glass 2010). For example, Palmitic Acid (PA) is a saturated fatty acid 
with a role in atherogenesis and T2D (Diaf, Khaled et al. 2015). In turn, this could sensitize 
monocytes/macrophages to be more responsive to a 2nd stimulus by factors associated with 
diabetes/metabolic disease (van Diepen, Thiem et al. 2016).  
We investigated the effect of glucose on the training of macrophages by measuring gene 
expression of S100A9 and S100A12 (Fig. 32). LPS induced expression of both S100A9, 
S100A12 compared to non-stimulated controls. We observed that high glucose dramatically 
increased the expression levels of S100A9 in response to PA (9.9-fold). S100A12 was 
significantly up regulated by glucose in LPS stimulated cells (5.4-fold). Therefore, 
hyperglycemia works synergistically together with stimulation with TLR-ligands to induce 
expression of S100A9 and S100A12. This indicates that S100 proteins are sensitive to glucose 
programming. 
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Figure 32. Programming of mature macrophages overnight with cytokines, fatty acids and/or 
TLR-ligands. RT-PCR analysis of IL-6, IL-10, S100A9, –A12 and IL-1β mRNA expression M0 
macrophages cultured for 6 days cultured under normal (NG, 5mM) and high glucose (HG, 25mM) 
conditions and stimulated overnight with TLR-ligands. Data present mean ± SD normalized to 
18SrRNA levels, n = 8. Significance is indicated in the figure by two-way ANOVA followed by 
Sidak's multiple comparisons test. P-values in the text belonging to this figure are according to 
student’s t-test. 
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4 DISCUSSION 
4.1 Regulation of S100 protein expression in macrophages under NG and HG 
conditions 
Hyperglycemia enhances the expression levels of S100A9, S100A12 among other genes in 
macrophages. S100A9 and S100A12 were significantly higher expressed in M1 macrophages 
and lower in M2 macrophages. The expression of S100 mRNA drops during differentiation in 
all types of macrophages. But on the late stages of differentiation IFNγ again induces S100 
gene expression. In addition, HG glucose increases the expression in M1 macrophages after 6 
days.  
Further, under HG conditions the correlation between S100A9 and S100A12 expression 
decreased in favour of S100A9. Lorenz et all. described this correlation of protein levels in 
acute and chronic lung disease (Lorenz, Muhlebach et al. 2008). Increased expression of 
S100A12 in acute respiratory distress syndrome suggested that S100A12 is more important in 
the onset of neutrophil influx and less elevated in chronic inflammation, whereas in sputum of 
cystic fibrosis and COPD patients higher levels of S100A8/A9 expression than S100A12 
indicating that chronic infection might be mediated by S100A8/A9 (Lorenz, Muhlebach et al. 
2008). We believe the regulation of expression and ratio of the two different genes might 
provide more insight in the mechanism of inflammation.  
Differences in protein expression relate to different donor responses, though on average 
macrophages contain high levels of intracellular S100 proteins and protein expression had not 
changed significantly by stimulation with cytokines or culture under high glucose. According 
to literature, protein levels of S100A8 and –A9 but not mRNA, are increased upon LPS/IFNγ 
stimulation in macrophages. In this study, cells were stimulated for 24h only (Averill, 
Barnhart et al. 2011). Our antibody for S100A12 was specific but our antibody for S100A9 
showed also the presence of homodimer and heterodimer with S100A8. Variability has been 
observed for recombinant proteins as well and partly, the presence of monomers might result 
from the dissociation of homodimers and heterodimers caused by SDS in nonreducing gels 
(Ryckman, Vandal et al. 2003). In the cell calcium levels are low. But after secretion, in the 
presence of extracellular calcium the heterodimer complex form tetramers and failure to 
tetramerize was associated with lack of functional activity (Leukert, Vogl et al. 2006). It was 
found that this formation of tetramers due to extracellular Ca+ is the auto inhibitory 
mechanism. The activity of heterodimers released by activated phagocytes at local site of 
inflammation, are restricted by tetramerization due to which the TLR4/MD2 binding site is 
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hidden (Vogl, Stratis et al. 2018). However, HG-induced oxidative stress has shown to 
increase Ca-influx in the cell via TRP-channels (Wuensch, Thilo et al. 2010) but additional 
effect on intracellular S100 protein levels remains to be tested. Another possible reason for 
discrepancy between mRNA and protein expression might be additional regulation on the level of 
translation. 
When intracellular levels of protein are high and not secreted more regulation might happen 
on the level of posttranslational modifications. S100 proteins can undergo different 
modifications but key seems to be their regulation through oxidative changes on their Cys 
residues (Lim, Raftery et al. 2009). S100A8 and –A9 are oxidized by peroxide, hypochlorite 
and NO however S100A12, which lacks Met and Cys residues, is susceptible for changes by 
oxidative environment (Goyette and Geczy 2011). NO production, mediated by iNOS in 
activated macrophages, is key in antimicrobial defence (Xue, Yan et al. 2018). Too much 
oxidative stress might be prevented through S-nitrosylation of thiols by NO (Biswas, Chida et 
al. 2006). S100A8 and S100A9 were found to be readily S-nitrosylated. But unlike iNOS, 
LPS and IFNγ stimulation in macrophages did not induce S100A8, therefore when ROS is 
needed for antimicrobial defence, S100A8 is not produced and in this case does not scavenge 
NO (Lim, Raftery et al. 2008). This modifications can regulate different functions of S100 
proteins (Goyette and Geczy 2011) but also convert short term NF-κB activation or oxidative 
stress into long-lasting activation of cells during pathological conditions as has been 
suggested for Nε-carboxymethyllysine(CML)-modification of S100 proteins due to oxidative 
and carbonyl stress can cause, in inflammatory bowel diseases (Andrassy, Igwe et al. 2006). 
Mild oxidation can be transient. Reversibility of oxidation reactions occurs through specific 
reductases e.g. glutathione or Met sulfoxide reductases and peroxiredoxins  (Forman, Fukuto 
et al. 2004). TXNIP (thioredoxin interacting protein) is up regulated by glucose in all types of 
MF, but highest in M1 macrophages (KM thesis ref). The reductase functions as an important 
regulator of S-Nitrosylation (Forrester, Seth et al. 2009) and HG-induced TXN mediated 
inflammasome activation in U937 monocytes (Tseng, Vong et al. 2016). 
The secreted levels of S100A9 and S100A12 in our cell culture model was much lower than 
serum levels identified in diabetic patients (Bouma, Lam-Tse et al. 2004, Nagareddy, Murphy 
et al. 2013, Ingels, Derese et al. 2015). In healthy individuals they are already 30 times higher 
and during inflammation local concentrations raise up to 80µg/ml (Frosch, Strey et al. 2000). 
It seemed that macrophages cannot release the intracellular accumulated S100 protein and 
might need an addition trigger from the in vivo microenvironment to be able to secrete the 
S100 protein e.g., cytokines, Fatty Acids (FA), AGEs or direct contact with activated 
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endothelium. Alternatively, S100 proteins have more intracellular functions (Xia, Braunstein 
et al. 2018).  
Secretion of S100 proteins does not follow classical ER/Golgi route but is released after PKC 
activation through inflammatory stimuli and is energy and calcium dependent (Rammes, Roth 
et al. 1997). DAMPs are passively released from necrotic cells whereas active release occurs 
in vivo as well as in vitro in activated cells i.e. granulocytes. Upon activation by PMA or 
TNFα, S100A12 translocates from cytoplasm toward the plasma membrane. S100A12 lacks 
the signal peptide for secretion via ER and the Golgi apparatus though inhibition of protein 
kinase activity or inhibition of tubulin polymerization blocked S100A12 release (Foell, 
Wittkowski et al. 2013). For S100A9, secretion is promoted through stimulation with IL-10 
and TNFα (Diercks, Hauschildt et al. 2013, Chakraborty, Bjork et al. 2015). Whereas 
especially IL-10 alone, promoted surface localization and TNF-α was needed for release 
(Diercks, Hauschildt et al. 2013). S100A9 alone is detected at the surface whereas 
S100A8/A9 heterodimer co-fractions intracellular with endolysosomes (Chakraborty, Bjork et 
al. 2015). Diercks et al. suggest that activation of MAPK38 by IL-10 (Lee and Chau 2002) 
might induce phosphorylation of S100A8/A9 which has shown to promote translocation to the 
plama membrane (Lominadze, Rane et al. 2005). Phosphorylation of MRP14 is 
antagonistically regulated by binding of MRP8 and calcium (Vogl, Ludwig et al. 2004). Only 
the phosphorylated form of S100A9 in the complex can induce proinflammatory cytokine 
expression and secretion (Schenten, Plançon et al. 2018). Lastly, both release of S100A9 and 
A12 from PMA-stimulated neutrophils depended on ROS production and K
+ 
efflux from 
ATP-sensitive K
+
 channels, just like IL-1β (Tardif, et al. 2015). Here S100A12 expression 
and secretion was very early upon response to  PMA, TNFα and LPS respectively (Foell, 
Wittkowski et al. 2013) and S100A8/A9 peaked after 24 to 48h of stimulation (Diercks, 
Hauschildt et al. 2013, Chakraborty, Bjork et al. 2015). The increased secretion of S100A9 
after 24h depends on few strong responding donors only and might be associated with 
monocyte adhesion still or be stimulated by endogenous TNF-α release (Moganti, Li et al. 
2017) or glucose induced ROS (Tardif, #xe9 et al. 2015, Rendra, Riabov et al. 2019). In our 
hands, IFNγ did not induce secretion higher than in the unstimulated cells. Similar to one 
study with murine macrophages, where IFNγ was found to induce S100A8 but not S100A9 
expression beside LPS and TNF, and declined slowly over 96h. Monomeric S100A8 was 
secreted by cells stimulated with IFNγ or TNFα but S100A9 or S100A8/A9 heterodimers 
were not detected (Xu and Geczy 2000). After 6 days we may measure only accumulation in 
supernatants, there is no literature on reuptake or autocrine effects. Interestingly IL-4 seems to 
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have an opposite effect on S100A9 compared to S100A12 release after 6 days. This might be 
due to anti-inflammatory functions of S100A9 as well and therefore uncontrolled secretion 
might point to a dysregulation of inflammatory functions (Austermann, Friesenhagen et al. 
2014). In general, secretion of S100A9 and S100A12 is not dependent on each other, and 
depends on agonist as well as cell type (Tardif, Chapeton-Montes et al. 2015).  
 
4.2 S100 expression in diabetic patients  
We examined whether S100 genes are higher expressed and therefore relevant in prediabetic 
and diabetic patients. S100A9 tend to be higher expressed in T2D whereas S100A12 was 
higher expressed in T1D patients but not to a significant level. Other factors in vivo may act 
stronger than glucose e.g. fatty acids, TLR ligands although no correlation between S100A9 
and S100A12 expression was found with BMI or body weight either. Another possible reason 
might be effect of the treatment of the patients receive (Rendra, Riabov et al. 2019).  
However also in prediabetic individuals we did not find a correlation of S100A9 and S100A12 
expression with HbA1c. However, as we can see from Fig. 7 though FG levels were not as 
well as HbA1c levels were not as high as seen in patients. However, similarly to the in vitro 
results, in patient monocytes, S100A9 and S100A12 expression were very tightly correlated 
in T1D, T2D and healthy controls (P < 0.0001 for all three) but not in prediabetic individuals 
(Table 18).  
Monocytes are usually classified into three subtypes based on CD14 and CD16 expression; 
non-classical monocytes (CD14-, CD16+) and high in classical (CD14+, CD16-) and highest 
in intermediate monocytes (CD14+, CD16+) (Mukherjee, Kanti Barman et al. 2015). By 
FACS we did not find significant difference in monocyte populations between controls and 
T2D. This is according to a study with prediabetic individuals with low prevalence of 
cardiovascular problems (Fadini, Cappellari et al. 2013). Authors observed no difference in 
percentages of classical, non-classical and intermediate monocytes. However, there was an 
increase in CD68 positive (M1 marker) cells which correlated with HbA1c (Fadini, Cappellari 
et al. 2013). For the association of S100 proteins in diabetic patients with late complications, 
often plasma levels are measured (Pedersen, Nybo et al. 2014, Dong, Shi et al. 2015). We 
found that S100A9 was hardly expressed in non-classical monocytes and high in classical and 
highest in intermediate monocytes. Also, we observed highest absolute increase in S100A9 
expression in the intermediate monocytes of T2D compared to healthy controls. Highest 
expression of S100A9 has been found before in classical monocytes but expression greatly 
varied between single cells (Yang, Anholts et al. 2018) 
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In our PBMCs from T2D diabetic patients which were analysed by flow cytometer, we also 
find S100A9 and S100A12 expression was enhanced. Expression of S100A12 was especially 
increased in the group with known CVD. S100 proteins have been linked with cardiovascular 
disease before but often circulating levels were measured (Burke, Kolodgie et al. 2004, Basta, 
Sironi et al. 2006, Schiopu and Cotoi 2013). Serum and mucosal S100A8/A9 and S100A12 
are elevated in patients with inflammatory bowel disease and therefore widely used as 
diagnosing marker (Leach, Yang et al. 2007). Plasma levels of S100A12 were also related to 
retinopathy in patients with T2D  (Dong, Shi et al. 2015) and circulating soluble RAGE 
(sRAGE) was found to be inversely correlated with S100A12 protein and correlated to 
glycemic control in patients with T2D (Basta, Sironi et al. 2006). Two other studies find 
plasma levels S100A8/A9 positively correlated with diabetic measures of IR, fasting blood 
glucose and impaired glucose metabolism (Ortega, Sabater et al. 2012) and HbA1c levels 
(Cotoi, Dunér et al. 2014). And in another study involving T2D patients, the higher 
concentrations of plasma S100A8/A9 were also associated with obesity, metabolic syndrome 
and associated but not predict cardiovascular problems i.e. neuropathy, peripheral arterial 
disease and myocardial ischemia (Pedersen, Nybo et al. 2014). Other clinical and mouse 
studies on the role of S100A8/A9 in cardiovascular diseases are reviewed (Schiopu and Cotoi 
2013).  
 
4.3 Regulation of S100 expression on epigenetic level 
Hyperglycemia enhanced increase of activating histone modifications H3K4me1, H3K4me3 
and AceH3 was similar at promoters of S100A9 and S100A12 in M1 macrophages. The level 
of AceH3 had significantly increased at both S100A9 and S100A12 promoters. Donors 
responded very heterogenous. In some of them studied epigenetic marks correlated to gene 
expression changes.  
H3K4me1 is known to function as distal mark (Barski, Cuddapah et al. 2007), whereas 
H3K4me3 is a promoter mark (Dong, Greven et al. 2012). H3K4me1 association was similar 
over several distances of TSS of S100 promoters whereas the highest association of 
H3K4me3 and AceH3 are seen near the TSS. The effect of H3K4me3 on transcription was 
once studied by specifically inducing PRDM9 methyltransferase writing only H3K4me3. 
Researchers were able to increase H3K4me3 at specific promoter site and thereby up regulate 
transcription ICAM1, RASSF1a and EpCAM in HEK293T, A549 and A2780 cells (Cano-
Rodriguez, Gjaltema et al. 2016). Successful upregulation of transcription however depended 
on the TSS site being DNA hyper methylated or H3K4me3 not already been enriched (Cano-
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Rodriguez, Gjaltema et al. 2016). S100A9 and S100A12 promoter do not contain CpG-
islands. Dense DNA-methylation on cytosine’s of CpG dinucleotides, predominantly 
concentrated in CG-islands (CGI) (Deaton and Bird 2011) and low CpG genes have shown to 
be less predictable (Dong, Greven et al. 2012).  
Also in RAW 264.7 macrophage-like cells stimulated with LPS, it has been shown that high 
and ongoing transcription was marked by either H3K79me2 or H3K36me3 and showed 
specific enrichment of motifs recognized by the NF-kB and IRF proteins (Soldi, Mari et al. 
2017). Therefore, another reason that we did not observe strong association with transcription 
might be that H3K4me3 and transcriptional initiation are tightly linked but elongation of 
RNApII afterwards might occur through methyltransferases recognizing H3K36me3 (Li, 
Carey et al. 2007). H3K36me can function according general mechanism as H3K4me but is 
usually located in the gene body and specific co-association was found of H3K4me1 with 
H3K36me2/K36me3. This highlights the importance of location and combination of histone 
marks (Soldi, Mari et al. 2017).  
AceH3 was mostly and significantly affected by glucose or metabolic changes at the average 
of 4 donors and different promoter regions. As a consequence, this loosens chromatin and less 
nucleosomes that were cross-linked to DNA, as reflected by our immunoprecipitation for total 
H3. For half of the donors, it was observed that elements gaining AceH3 starting from lower 
levels, in concert gain H3K4me1 whereas H3K4me3 remained relatively constant, as was 
seen before (Saeed, Quintin et al. 2014). BMDM from T1D mice also show increased total 
HAT activity and decreased HDAC activity relative to control macrophages (Filgueiras, 
Brandt et al. 2017). H3 contains more sites of acetylation. In yeast, at different histones both 
hyper- and hypoacetylation correlated to gene transcription, whereas acetylation at specific 
residues negatively correlates with increased transcription, although this was mostly seen at 
H4 (Kurdistani, Tavazoie et al. 2004). Unique acetylation patterns at single sites, mediate 
preferential TF binding and cluster in functional categories of genes (Kurdistani, Tavazoie et 
al. 2004).  
Additional epigenetic mechanisms that regulate expression of these genes include enhancers 
and might be taken in consideration in further studies. Also, most cited studies refer to 
genome wide studies or have been performed in cell lines where not individual donor 
responses and genetic differences play a role. 
Cultivation of macrophages in the presence of high glucose culture the level of total H3. The 
change in levels of total endogenous H3 is positively correlated to fold change increases in 
gene expression, whereas at some single promoter regions an almost linear correlation was 
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observed. Nucleosomes exclude TFs from binding the DNA and therefore are general 
repressors of gene transcription (Mao, Brown et al. 2011). Levels of total H3 unexpectedly 
positively correlated to fold change increases in the expression of S100A9 and S100A12. The 
strongest correlation was found for S100A9. Therefore, S100A9 transcription seems to be 
tightly regulated by nucleosome density. The positive effect of nucleosome density in our 
study is not intuitive and indicates that the general rule of activating and repressing marks is 
not valid in exceptional cases or acts independently from each other. In one study, where 
nucleosome density on a specific promoter was manipulated by changing GC content - 
occupancy increases with GC% of intrinsic DNA sequence -, the lowest GC% also did not 
correlate to highest output i.e. promoter activity (Parikh and Kim 2013). Nucleosomes are not 
bound 100% of the time but assemble and disassemble in equilibrium. Positioning is defined 
by DNA sequence and not changeable, but occupancy varies genome wide and gene 
specifically. A reduction in nucleosome number therefore can increase the variability of 
relative occupancy since the histone pool is finite (Celona, Weiner et al. 2011). Relative high 
occupancy together with high DNA accessibility has been described before and were not 
necessarily correlating with each other (Mieczkowski, Cook et al. 2016). Authors suggest this 
might be due to low stability of nucleosomes in regions which are often marked with active 
chromatin marks i.e. acetylation, but also increased chromatin remodelling can induce an 
increase in inter-nucleosomal spacing (Mieczkowski, Cook et al. 2016). Nucleosome 
depletion also increased 15% but not affected expression of 75% genes in yeast switched to 
glucose medium. These could be genes that are already induced, or the transcriptional 
activators and repressors may be dominant in gene regulation (Wyrick, Holstege et al. 1999).  
Activators of transcription are believed to act by recruitment of chromatin remodellers 
(Harikumar and Meshorer 2015) which promote nucleosome removal (Boeger, Shelansky et 
al. 2015). Chromatin remodelling complexes such as SWI/SNF complex accommodate single 
nucleosomes and their action is coupled to ATP hydrolysis which biases the spontaneous 
unwrapping of the DNA (Becker and Workman 2013, Parikh and Kim 2013, Boeger, 
Shelansky et al. 2015). At last, one key player in macrophages DNA wrapping is high 
mobility group box1 (HMGB1). It resides in nucleus but is secreted after LPS/IFNγ stimulus 
reducing histone content and activating transcription  (De Toma, Rossetti et al. 2014). It was 
found to be sensitive to and activated by exposure to high glucose (Chen, Qiao et al. 2015). 
Therefore, different mechanisms might play a role in our study though it is clear that histone 
content is critical in interpreting chromatin organization as it constitutes of an extra layer of 
epigenetic regulation.  
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4.4 Manipulation of S100 expression by targeting histone modifying enzymes.  
We see the different effects of inhibition of HMTs. Inhibition of SET7 down regulated 
S100A9 and S10012 expression, while SMYD3 inhibition was specific for S100A12 in the 
same donors. Inhibitions of MLL tend to increase expression increased S100 expression.  
The key histone methyltransferase that is activated by hyperglycemia is SET7/9 and writes the 
H3K4me1 activation marks. SET7 is involved in inflammatory signalling and found to be a 
co-activator of NF-B in macrophages. DMSO alone did not change expression of S100A9 
and S100A12, however a slight decrease has been seen in all the experiments with HMT 
inhibitors and especially were PFI-2 was applied. The highest concentration of DMSO used in 
this study was 0.002%. No cytotoxicity of DMSO though has been found up to 10% in 
BMDM (Ahn, Kim et al. 2014) and hardly change of gene expression profiles up to 0.5% in 
human hepatocytes (Sumida, Igarashi et al. 2011). However, DMSO might have anti-
inflammatory effects and inhibit cytokine production (Ahn, Kim et al. 2014). Possible 
mechanisms for the anti-inflammatory properties of DMSO suggested include ROS 
scavenging (Santos, Figueira-Coelho et al. 2003, Xiang, Zhao et al. 2018), NF-κB inhibition 
(Chang, Llanes et al. 1999) and intracellular calcium reduction (Santos, Figueira-Coelho et al. 
2003).  Gene silencing of SET7 attenuated TNF-α induced H3K4me and recruitment of NF-
B p65 to inflammatory gene promoters in THP-1 cells as well as in macrophages from 
diabetic mice (Li, Reddy et al. 2008). SET7 expression was increased and H3K4me1 on NF-
kB p65 promoter was associated with expression of NF-kB-dependent oxidant/inflammatory 
genes COX2 and iNOS in PBMCs form T2D patients (Paneni, Costantino et al. 2015). 
However, many also non-histone proteins are regulated by SET7 and its biological outcome 
depends on the specificity of the TF target (Batista and Helguero 2018). Also, SET7 
inhibition by PFI(2) compound depends on SAM availability (Kaniskan, Martini et al. 2017). 
SET7/9 knockdown attenuated adhesion to TNF-α-treated HUVEC monolayers before (Li et 
al., 2008). Therefore, SET7 is an inflammatory mediator and glucose sensor. 
WDR5 is part of complex that stimulates the catalytic activity of HMTs. This WRAD 
complex exists separate from MLL enzymes and has additional interactions partners and 
functions in the cells (van Nuland, Smits et al. 2013). Members of the MLL family show 
preferential methylation levels and this is according to their localization in the chromatin e.g., 
SET1A and B are found at promoter and preferential trimethylate whereas MLL3 and 4 
localize at enhancer regions as is H3K4me1 (Bochynska, Lüscher-Firzlaff et al. 2018). 
H3K4me1 at the promoter region is even suggested to induce transcriptional silencing and 
restrict H3K4me3 reading, in macrophages among other cell types, although it is not clear 
DISCUSSION 
87 
 
whether this is provoked by MLL3/4 or the remaining methylation after demethylase activity 
(Cheng, Blum et al. 2014, Bochynska, Lüscher-Firzlaff et al. 2018). This could be an 
explanation for the negative correlation of H3K4me1 with increased gene transcription. The 
authors also observed that H3K4me1 for a group of acutely inducible genes, was mediated by 
MLL3/4 and loss of this HMT even promoted stimulus-dependent i.e. LPS induced gene 
expression without changes in H3K4me3 levels (Cheng, Blum et al. 2014). Then, the function 
of the modification is largely defined by the effector or reader protein and might explain our 
observation that MLL inhibition did not reduce but even increased gene expression of 
S100A9 in high glucose conditions.   
Specific recruitment seems more likely to occur through the specific subunits of the MLL 
protein family members and might be reached by sequence specific TFs (Table 2 in 
(Bochynska, Lüscher-Firzlaff et al. 2018). MLL proteins possess e.g. CXXC zinc finger 
domains to bind unmethylated CpG islands as well as an AT-hook region or high mobility 
group 1 binding motifs - or interaction with chromatin via PHD fingers, bromodomains or 
WD40 (Bochynska, Lüscher-Firzlaff et al. 2018). The MLL1 and MLL2 complexes both 
contain the tumour suppressor gene menin. In macrophages enhancer transcription was linked 
to H3K4 methylation and TLR4 signalling which depended on MLL1, 2/4 and 3 (Kaikkonen, 
Spann et al. 2013). Also, differentiation of macrophage into M0, M1 and M2 showed specific 
upregulation of MLL HMTases and KDM6B demethylase in M1 macrophages and regulate 
CXCL10 expression, which could be blocked using a MLL-Menin inhibitor (Kittan, Allen et 
al. 2013). Notably, HG induced S100 gene expression and regulation of S100 gene expression 
by MLL enzymes showed to be synergistic for S100A9, pointing out pro-inflammatory 
activation in cultured monocyte/macrophages by glucose. Inhibiting the menin pathway has 
been suggested before as diabetes treatment (Jen and Wu 2008).  
Expression of SMYD3 is up regulated in M0 and M2 compared to M1 macrophages (Kittan, 
2013). SMYD family of proteins contains five members and methylate histones as well as 
non-histone targets (Spellmon, Holcomb et al. 2015). SMYD2 facilitates H3K36me2 and 
negatively regulates TNF and IL-6 promoters in macrophages inhibits NF-κB and ERK 
signalling (Xu, Liu et al. 2015). In addition, trimethylation at H4K20 by SMYD5 represses 
TLR4 target genes in macrophages through its association with NCoR co-repressor complex 
(Stender, Pascual et al. 2012). SMYD3 however, despite existing literature does not methylate 
H3K4 but far more efficiently methylates H4K5 (Van Aller, Reynoird et al. 2012) and is 
mainly involved in regulation of transcription and signal transduction pathways promoting 
cancer development (Mazur, Gozani et al. 2016). SMYD3-mediated methylation of MAP3K2 
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promoted the activation of the Ras/Raf/MEK/ERK signalling module in cancer cell lines 
(Mazur, Reynoird et al. 2014). In this study we show that SMYD3 has effect on specifically 
S100A12 promoter but not on S100A9. Signalling by SMYD3 in diabetic conditions has not 
been addressed.  
This indicate that epigenetic target enzymes control the levels of pro-inflammatory factors 
(S100 proteins) induced by HG. It remains to be studied if reduction of S100 expression by 
inhibition of these enzymes correlates with reduction of diabetes severity in preclinical 
models. 
4.4 The involvement of metabolic memory in the expression of S100 proteins 
In our memory model M1 macrophages were cultured for six days and medium was changed 
and cells were harvested at day twelve for analysis. Transient hyperglycemia caused 
memorable changes of S100 genes, especially S100A12 expression that last when glucose 
concentrations are normalized. This type of metabolic memory was not observed for other 
pro-inflammatory factors CCR2 and IL1B.  
When consequences of glycemic events are not normalized with normalizing blood glucose, 
within the duration of protein half-life or cellular turnover and potentially accumulate with 
repeated events. Combined this is known as the metabolic memory that is caused by diabetes 
(Hansen, Hansen et al. 2017, Testa, Bonfigli et al. 2017). Endogenous stimuli from the 
diabetic environment through epigenetic changes could contribute to training of macrophages 
and this can already occur in the bone marrow (El-Osta 2012, van Diepen, Thiem et al. 2016).  
On the epigenetic level, association of H3K4me3, AceH3 as well as total H3 with the 
promoter of both S100A9 and S100A12 were decreased in M1 macrophages cultured 
continuously under HG conditions for 12 days. H3K4me1 for S100A9 and H3K4me3 for 
S100A12 were sustained in transient hyperglycemia.  
After 12 days the epigenetic picture is different compared to 6 days. This could be either 
effect of medium change or chronic exposure to HG, which probably switches on an negative 
feedback mechanism that start to inactivate chromatin by a decrease in activating marks on 
the promoter of pro-inflammatory genes. H3K4me1 for S100A9 and H3K4me3 for S100A12 
possibly mark metabolic memory. H3K4me1 has been associated with epigenetic memory 
and/or trained immunity in macrophages before but in opposite manner; it was found that 
elements that loose the H3K27ac not loose H3K4me1 (Saeed, Quintin et al. 2014). It might be 
that glucose induced S100A12 expression is involved in training processes. Enhancers also 
may provide a mechanism for epigenetic memory based on their responses to different 
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stimuli. Latent enhancers, after washout of the stimulus, showed a residual sustained 
H3K4me1 although PU.1 and acetylation were lost which was associated with more rapid and 
intense induction upon restimulation (Ostuni, Piccolo et al. 2013). Similar, we observed that 
the change in AceH3 as well as total H3 was reversible and therefore seems to be more 
dynamic and responsive to metabolic changes. That the changes on gene expression level are 
not as fast as changes in epigenetic marks could then be a consequence of stabilisation of 
RNA.  
To conclude, memorable changes in S100 gene expression might mediate detrimental effects 
of chronic hyperglycemia even if glucose levels return to normal range.  
 
4.5 Glucose sensitizes macrophages to the action of exogenous and endogenous pro-
inflammatory factors 
LPS induced expression of both S100A9, S100A12 compared to non-stimulated controls. We 
observed that high glucose dramatically increased the expression levels of S100A9 in response 
to PA and of S100A12 in LPS stimulated cells. Therefore, hyperglycemia works 
synergistically together with stimulation with TLR-ligands and S100 proteins are sensitive to 
glucose programming. It has been shown before that high glucose induces a priming effect in 
macrophages and sensitizes cells towards inflammatory response (Grosick, Alvarado-Vazquez 
et al. 2018, Pavlou, Lindsay et al. 2018). It might be that due to the fact that glucose directly 
elevates the expression of TLRs (Dasu, Devaraj et al. 2008). Another possible explanation 
would be that chromatin on S100 promoters is already opened and the presences of secondary 
pro-inflammatory mediators dramatically induce the expression of these genes. Probably, both 
metabolic and epigenetic changes contribute to observed effects at a few levels in this study.   
Firstly, since glucose metabolism determines immune cell activation and also long-term 
training of monocytes via the AKT–mTOR–HIF-1a pathway (Cheng, Quintin et al. 2014) it 
had been hypothesized that high circulating levels of glucose could program immune cells 
towards an inflammatory phenotype through increased glucose utilization via glycolysis (van 
Diepen, Thiem et al. 2016). However, we observed that culture in high glucose conditions did 
not change glucose uptake of M0 and M1 macrophages (paragraph 3.2.1), and it has been 
suggested before that increased glucose supply, i.e.  increased uptake alone are not sufficient 
to drive inflammatory activation and atherosclerosis in myeloid cells (Vallerie and Bornfeldt 
2015). Instead, overutilization of glucose via glycolytic enzyme pyruvate kinase M2 (PKM2) 
which phosphorylates STAT3 in turn, has been shown in macrophages of patients with 
coronary artery disease (Shirai, Nazarewicz et al. 2016). Likewise, in BMDM macrophages 
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after long term culture under high glucose conditions mitochondrial functions and basal 
glycolysis were not affected, but cells showed impaired glycolytic capacity i.e. the maximum 
rate of conversion of glucose to pyruvate or lactate. The glycolytic reserve is an important 
source of energy in cases of ATP demand. When proinflammatory response depends on 
glycolysis e.g. NADPH production for ROS and NO, the limited energy supply translates into 
impaired functions (Pavlou, Lindsay et al. 2018).  
Second, several metabolic characteristics of M1 macrophages i.e. ROS, NO and succinate, are 
important demethylase inhibitors and inhibiting glycolysis or stimulating mitochondrial 
metabolism reduced the formation of HDAC inhibitor lactate (Baardman, Licht et al. 2015). 
This might provide a link between metabolism and AceH3 levels in our study.  
Third, hyperglycemia-induced ROS and methylglyoxal production has shown do regulate 
expression of RAGE, S100A8, S100A12, and HMGB1 expression, which was normalized by 
overexpression of UCP1, SOD2, or GLO1. Loss of GLO1 mimicked the effect of high 
glucose whereas overexpression of GLO1 normalized the increased binding of NFκB p65 and 
AP-1 to the respective promoters (Yao and Brownlee 2009), which might be mediated by 
SET7 (Yang, Huang et al. 2009). At last, overexpression S100A8 and -A9 led to increased IL-
10, where TN-α and IL-1β did not change (Yang, Anholts et al. 2018). IL-10 mediates many 
anti-inflammatory effects in macrophages, but also has a role in metabolic programming; it 
inhibits glycolytic flux by inhibiting translocation of GLUT1 to the membrane and in LPS-
stimulated murine BMDMs (Ip, Hoshi et al. 2017).  GLUT1 seems to be the primary rate-
limiting glucose transporter for proinflammatory macrophages (Freemerman, Johnson et al. 
2014) which expression had not changed (GSE86298 by (Moganti 2017). On the other side 
we find ARRDC4 together with TXNIP highly up regulated under high glucose conditions. 
Both are able to inhibit glucose uptake and lactate output in adipocytes and skin fibroblasts 
(Patwari, Chutkow et al. 2009) and therefore might provide another mechanism by which 
macrophages regulate glucose metabolism. 
To summarize, a strong upregulation of S100 proteins by endogenous and diabetes-relevant 
ligands in HG glucose conditions suggests that they can be important players in diabetes-
related inflammation. 
4.6 Conclusion and outlook 
Glucose primes macrophages towards increased inflammatory response, whereas 
hyperglycemia causes memorable changes of S100 genes expression that last when glucose 
concentrations are normalized. S100 proteins have pleiotropic functions in immune cells. 
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S100A8 and S100A9 seem to have more protective effects in regulation of inflammation, 
whereas S100A12 is rather pro-inflammatory (Bowman, Wilk et al. 2010, Goyette and Geczy 
2011). Glucose inhibits its down regulation during maturation, and this is accompanied with 
epigenetic changes at the promoters. HMTs play a role in metabolic induced changes in 
polarized macrophages. S100A8/A9 is involved in tolerance and negative feedback of 
inflammation (Austermann, Friesenhagen et al. 2014). Its increase under high glucose 
conditions seems a protective mechanism of the macrophage to reduce excessive 
inflammation. A suggested order of events by Schiopu et all. is that traditional cardiovascular 
risk factors like smoking, dyslipidemia, hyperglycemia and obesity directly or indirectly 
elevate S100A8/A9 production and stimulate myeloid cell production in the bone marrow 
(Nagareddy, Murphy et al. 2013) as well as their recruitment to the vessel wall via endothelial 
activation (Viemann, Strey et al. 2005) and increased expression of integrin’s (Eue, Pietz et 
al. 2000, Bouma, Lam-Tse et al. 2004). Local levels of S100 proteins may be deposited by 
leukocytes and S-nitrosylation by NO coming from EC may regulate function, but, in turn, 
regulatory roles of S100A8/A9 is important resolution of inflammation, T cell tolerance, and 
tissue repair because of its co-dependence on IL-10 for induction and secretion, but also 
because of oxidant scavenging or ROS regulating capacities (Lim, Raftery et al. 2009).  
Individual differences in S100 protein expression in response to hyperglycemia and pro-
inflammatory stimuli suggest that S100 proteins can be used to distinguish between 
responders and non-responders towards hyperglycemia indicating the risks for later vascular 
complications in diabetes patients. Hyperglycemia can reprogram M1 macrophages via 
regulation of S100A expression on the epigenetic level. An upregulation of S100 proteins by 
endogenous and diabetes-relevant ligands in HG glucose conditions suggests that they can be 
important players in diabetes-related inflammation and their targeting (e.g. using inhibitors of 
chromatin-modifying enzymes) can reduce inflammation providing a benefit for diabetes 
patients. 
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5 SUMMARY 
The number of diabetic patients in Europe and world-wide is growing. Diabetes confers to 
about two-fold higher risk for a wide range of vascular diseases independently from common 
risk factors such as age, sex, smoking, high blood pressure, and BMI. Lack of insulin (T1D) 
or lack of insulin responsiveness (T2D) causes metabolic changes such as hyperglycemia 
(HG) which contributes to the pathology of diabetes. Macrophages are essential regulators of 
inflammation and play a critical role in diabetic macro- and microvascular complications. 
Previous work in our laboratory using Affymetrix chip profiling identified that hyperglycemia 
enhances the expression of several members of the S100 protein family in macrophages. 
S100A9 and S100A12 are pro-inflammatory molecules that activate endothelial cells. Their 
elevated levels in the circulation positively correlate with diabetes pathology. However the 
role of hyperglycemia in the production of S100A9 and A12 by macrophages was not 
investigated to date. The aims of the study were 1) to investigate the regulation of S100A9 
and - S100A12 expression during macrophage differentiation in normal and hyperglycemic 
conditions and diabetic patients; to examine the effect of hyperglycemia on the histone code 
on the promoters of S100A9 and S100A12 and the involvement of specific histone modifying 
enzymes; to examine potential hyperglycemic memory for the expression of S100A9 and 
S100A12 in macrophages.  
Human primary monocytes-derived macrophages were used and differentiated for 6 day in the 
presence of IFNγ or IL-4 to generate M1 and M2 macrophages respectively and without 
cytokines to generate M0 macrophages. Using RT-PCR it was demonstrated that S100A9 and 
–A12 are highly expressed in M1 macrophages compared to M2. Hyperglycemia increased 
the expression of S100A9 and S100A12 in M0 but mostly in M1 macrophages, up to 4.4-fold 
and 9.8-fold for individual donors respectively. Association for activating histone marks with 
the promoters of these genes was analysed by chromatin immunoprecipitation (ChIP). 
Hyperglycemia induced the increased association of activating histone marks; H3K4me1, 
H3K4me3 and general H3Ace with promoters of S100A9 and S100A12. Association 
correlated negatively with the increase in gene expression. The total H3, representing the 
nucleosome density, was reduced under HG conditions. The increase in total endogenous H3 
positively correlated to the fold change increases in gene expression of S100A9 and S100A12. 
Histone methyltransferases regulate gene expression in differentiated M1 macrophages. 
Application of inhibitors of the MLL complex increased S100 gene expression synergistically 
with glucose. Inhibition of SMYD3 specifically down regulated S100A12 expression. 
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Inhibition of SET7, the key histone methyltransferase that writes H3K4me1, down regulated 
both S100A9 and –A12 gene expression. Expression of SET7 and its translocation to the 
nuclei was increased in M1 macrophages and under high glucose conditions. In a macrophage 
model were glucose concentrations were changed to normal glucose concentration after 6 
days, and gene expression was measured on day 12, memorable changes of S100 genes 
expression in M1 macrophages were observed. In another model, where macrophages without 
polarizing factors are cultured in high glucose conditions for 6 days and subsequently 
stimulated overnight with TLR-ligands, increased expression of S10 protein was identified. 
S100A9 had increased in response to stimulation with PA (9.9-fold). S100A12 was up 
regulated in LPS stimulation of macrophages (5.4-fold).  
Therefore, increased expression of S100 proteins may be indicative for the long-term pro-
inflammatory effects of hyperglycemia. S100 proteins are expressed in M1 macrophage and 
their expression is up regulated in hyperglycemic conditions, whereas histone modifying 
enzymes SMYD3 and SET7 are involved. Also, histone code might regulate transcription 
independently from nucleosome density in our study and histone content constitutes of an 
extra layer of epigenetic regulation. At last, stimulation of hyperglycemia-exposed 
macrophages by TLR-ligands revealed that S100 proteins are sensitive to glucose 
macrophages programming. 
Individual differences in S100 protein expression in response to hyperglycemia and pro-
inflammatory stimuli suggest that S100 proteins can be used to distinguish between 
responders and non-responders towards hyperglycemia indicating the risks for later vascular 
complications in diabetes patients. S100 proteins can be considered as a target in chronic 
inflammatory conditions, and macrophage directed treatments that aim to reprogram M1 
macrophages, should take into account the level of induced epigenetic changes. 
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